[S02DA03, antipyrine, The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Drospirenone.]
[G03XB02, ulipristal, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Ulipristal.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Drospirenone is combined with Streptokinase.]
[J01GA01, streptomycin, Drospirenone may increase the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Drospirenone.]
[A02BX02, sucralfate, Drospirenone may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Drospirenone may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA16, sulbenicillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Sulbenicillin.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Drospirenone.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Drospirenone.]
[M04AB02, sulfinpyrazone, The metabolism of Drospirenone can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Drospirenone.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Sulindac is combined with Drospirenone.]
[N03AX03, sulthiame, The metabolism of Drospirenone can be increased when combined with Sulthiame.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Drospirenone.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Drospirenone.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Azapropazone is combined with Drospirenone.]
[J01CA15, talampicillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Talampicillin.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Drospirenone.]
[N05CD07, temazepam, Drospirenone may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Drospirenone.]
[R03CC03, terbutaline, Drospirenone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AE07, dabigatran etexilate, The risk or severity of adverse effects can be increased when Drospirenone is combined with Dabigatran etexilate.]
[G03BA03, testosterone, Drospirenone may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA02, tetracycline, The serum concentration of Drospirenone can be decreased when it is combined with Tetracycline.]
[L04AX02, thalidomide, Drospirenone may increase the thrombogenic activities of Thalidomide.]
[R03DA04, theophylline, Drospirenone may decrease the excretion rate of Theophylline which could result in a higher serum level.]
[P02CA02, thiabendazole, Drospirenone may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, Drospirenone may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Drospirenone.]
[N05CA19, thiopental, The metabolism of Drospirenone can be increased when combined with Thiopental.]
[G04BE06, moxisylyte, Drospirenone may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Drospirenone may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA13, ticarcillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Ticarcillin.]
[B01AC05, ticlopidine, Drospirenone may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, Drospirenone may increase the excretion rate of Timolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01AB02, tinidazole, Drospirenone may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA12, tobramycin, Drospirenone may increase the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Drospirenone.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Drospirenone.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Drospirenone.]
[N02AX02, tramadol, Drospirenone may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[B02AA02, tranexamic acid, Drospirenone may increase the thrombogenic activities of Tranexamic acid.]
[L01XF01, tretinoin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Tretinoin.]
[S01BA05, triamcinolone, The serum concentration of Triamcinolone can be increased when it is combined with Drospirenone.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Triamterene is combined with Drospirenone.]
[N05CD05, triazolam, Drospirenone may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Drospirenone may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AD02, trifluridine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Trifluridine.]
[D07AC02, fluclorolone, The serum concentration of Fluclorolone can be increased when it is combined with Drospirenone.]
[R03BA07, mometasone, The serum concentration of Mometasone can be increased when it is combined with Drospirenone.]
[A03AA05, trimebutine, Drospirenone may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AC02, trimethadione, The metabolism of Drospirenone can be increased when combined with Trimethadione.]
[J01EA01, trimethoprim, Drospirenone may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[J01FA08, troleandomycin, The metabolism of Drospirenone can be decreased when combined with Troleandomycin.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Drospirenone.]
[R03DX07, roflumilast, Drospirenone may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX04, ipilimumab, Drospirenone may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Drospirenone.]
[R02AA14, oxyquinoline, Drospirenone may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Drospirenone.]
[J05AP03, boceprevir, The serum concentration of Drospirenone can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Drospirenone can be decreased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Drospirenone can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of adverse effects can be increased when Drospirenone is combined with Urokinase.]
[S01AA28, vancomycin, Drospirenone may increase the excretion rate of Vancomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX21, ezogabine, The metabolism of Drospirenone can be increased when combined with Ezogabine.]
[B01AF01, rivaroxaban, The risk or severity of adverse effects can be increased when Drospirenone is combined with Rivaroxaban.]
[B01AC24, ticagrelor, The risk or severity of adverse effects can be increased when Drospirenone is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Drospirenone can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Drospirenone can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Drospirenone.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Drospirenone.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Drospirenone.]
[S01XA02, vitamin A, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Vitamin A.]
[B03BA01, vitamin B12, Drospirenone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[A11HA03, vitamin E, The metabolism of Drospirenone can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Warfarin.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Drospirenone.]
[J05AE02, indinavir, The metabolism of Drospirenone can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The metabolism of Drospirenone can be increased when combined with Levetiracetam.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Drospirenone.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Drospirenone.]
[M05BA05, tiludronic acid, Drospirenone may increase the excretion rate of Tiludronic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B06AC02, icatibant, Drospirenone may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Drospirenone.]
[B01AE01, desirudin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Drospirenone can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Drospirenone may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AE04, ziprasidone, The metabolism of Drospirenone can be decreased when combined with Ziprasidone.]
[S01AA13, fusidic acid, The metabolism of Drospirenone can be decreased when combined with Fusidic acid.]
[V03AC02, deferiprone, Drospirenone may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA01, aspirin, The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Drospirenone.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Drospirenone.]
[G04BD07, tolterodine, Drospirenone may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH04, doripenem, Drospirenone may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB03, atenolol, The risk or severity of hyperkalemia can be increased when Atenolol is combined with Drospirenone.]
[J02AC03, voriconazole, The metabolism of Drospirenone can be decreased when combined with Voriconazole.]
[M01CB03, auranofin, Drospirenone may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Drospirenone.]
[R07AX02, ivacaftor, The metabolism of Drospirenone can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The serum concentration of Prednylidene can be increased when it is combined with Drospirenone.]
[B03XA04, peginesatide, Drospirenone may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Drospirenone may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Drospirenone may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, Drospirenone may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA09, azlocillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Azlocillin.]
[J01DF01, aztreonam, Drospirenone may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Drospirenone.]
[M03BX01, baclofen, Drospirenone may increase the excretion rate of Baclofen which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA11, lorcaserin, Drospirenone may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD12, mirabegron, Drospirenone may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AX03, cobicistat, The serum concentration of Drospirenone can be decreased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Drospirenone can be decreased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Drospirenone can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Drospirenone is combined with Linaclotide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Drospirenone.]
[B01AX01, defibrotide, The risk or severity of adverse effects can be increased when Drospirenone is combined with Defibrotide.]
[H02AA01, aldosterone, The serum concentration of Aldosterone can be increased when it is combined with Drospirenone.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Drospirenone.]
[N05CA04, barbital, The metabolism of Drospirenone can be increased when combined with Barbital.]
[D02BA02, octinoxate, Drospirenone may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE04, nelfinavir, The metabolism of Drospirenone can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, Drospirenone may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA13, lercanidipine, The risk or severity of hyperkalemia can be increased when Lercanidipine is combined with Drospirenone.]
[N03AX22, perampanel, The metabolism of Drospirenone can be increased when combined with Perampanel.]
[V09IX04, fluorodeoxyglucose F18, Drospirenone may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[H01CB05, pasireotide, The metabolism of Drospirenone can be decreased when combined with Pasireotide.]
[V08CA11, gadofosveset, Drospirenone may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Drospirenone.]
[B01AF02, apixaban, The risk or severity of adverse effects can be increased when Drospirenone is combined with Apixaban.]
[A16AX08, teduglutide, Drospirenone may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Drospirenone.]
[C04AX11, bencyclane, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Bencyclane.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Drospirenone.]
[A16AX09, glycerol phenylbutyrate, Drospirenone may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Drospirenone.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Benorilate is combined with Drospirenone.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.]
[A06AX06, tegaserod, The risk or severity of adverse effects can be increased when Drospirenone is combined with Tegaserod.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Drospirenone.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Drospirenone.]
[L03AA12, ancestim, Drospirenone may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Drospirenone.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Drospirenone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Drospirenone.]
[N04AC01, benztropine, Drospirenone may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EC02, dabrafenib, The serum concentration of Drospirenone can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hyperkalemia can be increased when Benzydamine is combined with Drospirenone.]
[L01EE01, trametinib, Drospirenone may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX05, florbetapir F-18, Drospirenone may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX28, levomilnacipran, Drospirenone may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[C08EA02, bepridil, The risk or severity of hyperkalemia can be increased when Bepridil is combined with Drospirenone.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Drospirenone.]
[A05AA03, cholic acid, The therapeutic efficacy of Cholic Acid can be decreased when used in combination with Drospirenone.]
[C02KX04, macitentan, Drospirenone may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX26, vortioxetine, Drospirenone may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC08, etonogestrel, Drospirenone may increase the excretion rate of Etonogestrel which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AF04, eslicarbazepine, The metabolism of Drospirenone can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Drospirenone can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Drospirenone may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AG04, vigabatrin, The metabolism of Drospirenone can be increased when combined with Vigabatrin.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Drospirenone.]
[C01CA27, droxidopa, Drospirenone may increase the excretion rate of Droxidopa which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB04, acebutolol, The risk or severity of hyperkalemia can be increased when Acebutolol is combined with Drospirenone.]
[N05CH03, tasimelteon, Drospirenone may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA07, metreleptin, The metabolism of Drospirenone can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Drospirenone can be increased when combined with Apremilast.]
[L02BG02, formestane, Drospirenone may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA03, betamethasone, The serum concentration of Betamethasone can be increased when it is combined with Drospirenone.]
[S01ED02, betaxolol, The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Drospirenone.]
[B01AE03, argatroban, The risk or severity of adverse effects can be increased when Drospirenone is combined with Argatroban.]
[V03AB34, fomepizole, Drospirenone may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Drospirenone.]
[L04AC11, siltuximab, The metabolism of Drospirenone can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Drospirenone.]
[B01AC26, vorapaxar, The risk or severity of adverse effects can be increased when Drospirenone is combined with Vorapaxar.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Drospirenone is combined with Acenocoumarol.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Drospirenone.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Drospirenone.]
[V08AA01, diatrizoic acid, Drospirenone may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AA04, iothalamic acid, Drospirenone may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Drospirenone.]
[J01XA05, oritavancin, The metabolism of Drospirenone can be increased when combined with Oritavancin.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Drospirenone is combined with Phenolphthalein.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Drospirenone.]
[A06AH03, naloxegol, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Naloxegol.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Drospirenone.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Drospirenone is combined with Bisacodyl.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Drospirenone.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Drospirenone is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of adverse effects can be increased when Drospirenone is combined with Edoxaban.]
[N06AX11, mirtazapine, The metabolism of Drospirenone can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Drospirenone can be increased when combined with Secukinumab.]
[B06AC01, C1 esterase inhibitor (human), The risk or severity of thromboembolism can be increased when Drospirenone is combined with Human C1-esterase inhibitor.]
[B06AC04, C1 esterase inhibitor (recombinant), The risk or severity of thromboembolism can be increased when Drospirenone is combined with Conestat alfa.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Drospirenone.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Drospirenone.]
[N02BE01, acetaminophen, Drospirenone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC01, bleomycin, Drospirenone may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Drospirenone is combined with Tioclomarol.]
[J05AP06, asunaprevir, The serum concentration of Drospirenone can be decreased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Eluxadoline.]
[B01AC25, cangrelor, The risk or severity of adverse effects can be increased when Drospirenone is combined with Cangrelor.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Drospirenone.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Drospirenone is combined with Magnesium peroxide.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Drospirenone.]
[M02AA25, aceclofenac, The risk or severity of hyperkalemia can be increased when Aceclofenac is combined with Drospirenone.]
[M01AB11, acemetacin, The risk or severity of hyperkalemia can be increased when Acemetacin is combined with Drospirenone.]
[S01EC01, acetazolamide, The metabolism of Drospirenone can be increased when combined with Acetazolamide.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Drospirenone.]
[D05BB02, acitretin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Acitretin.]
[V03AB37, idarucizumab, Drospirenone may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Drospirenone.]
[J02AC05, isavuconazole, The metabolism of Drospirenone can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Drospirenone.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Drospirenone.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Drospirenone.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Drospirenone.]
[V03AB35, sugammadex, The serum concentration of Drospirenone can be decreased when it is combined with Sugammadex.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Drospirenone.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Drospirenone.]
[M04AB05, lesinurad, Drospirenone may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA05, aprobarbital, The metabolism of Drospirenone can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Alminoprofen is combined with Drospirenone.]
[N03AX23, brivaracetam, The metabolism of Drospirenone can be increased when combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Drospirenone.]
[N05BA08, bromazepam, Drospirenone may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Drospirenone.]
[A02AD05, aluminum magnesium silicate, Drospirenone may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA01, amlodipine, The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Drospirenone.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Drospirenone.]
[A05AA04, obeticholic acid, The therapeutic efficacy of Obeticholic acid can be decreased when used in combination with Drospirenone.]
[C03CA02, bumetanide, Drospirenone may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, Drospirenone may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA19, bupranolol, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Bupranolol.]
[N07BC01, buprenorphine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Buprenorphine.]
[N05BE01, buspirone, Drospirenone may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Drospirenone.]
[L01XX27, arsenic trioxide, Drospirenone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA03, clofezone, Drospirenone may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Butorphanol.]
[J01CE04, azidocillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Azidocillin.]
[L01XK03, rucaparib, The metabolism of Drospirenone can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Drospirenone can be decreased when combined with Azithromycin.]
[J01CA06, bacampicillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Bacampicillin.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Drospirenone is combined with Plecanatide.]
[L01EF02, ribociclib, The metabolism of Drospirenone can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hyperkalemia can be increased when Balsalazide is combined with Drospirenone.]
[A06AH05, naldemedine, Drospirenone may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, Drospirenone may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, The metabolism of Drospirenone can be increased when combined with Pregabalin.]
[N03AX30, beclamide, The metabolism of Drospirenone can be increased when combined with Beclamide.]
[C09AA07, benazepril, Benazepril may increase the hyperkalemic activities of Drospirenone.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Drospirenone.]
[D05AX03, calcitriol, The metabolism of Drospirenone can be increased when combined with Calcitriol.]
[P01CA02, benznidazole, Drospirenone may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF06, abacavir, Drospirenone may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE09, tipranavir, The metabolism of Drospirenone can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Drospirenone may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB02, infliximab, The metabolism of Drospirenone can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Drospirenone can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Drospirenone.]
[L04AC14, sarilumab, The metabolism of Drospirenone can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, Drospirenone may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF04, betrixaban, The risk or severity of adverse effects can be increased when Drospirenone is combined with Betrixaban.]
[D01AC10, bifonazole, The metabolism of Drospirenone can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, Drospirenone may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Drospirenone.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Drospirenone.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Drospirenone.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Drospirenone.]
[C07AB07, bisoprolol, Drospirenone may increase the excretion rate of Bisoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AG03, efavirenz, The metabolism of Drospirenone can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Bopindolol.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Canrenone is combined with Drospirenone.]
[R03BA02, budesonide, The serum concentration of Budesonide can be increased when it is combined with Drospirenone.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Bumadizone is combined with Drospirenone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Drospirenone.]
[J05AX18, letermovir, The metabolism of Drospirenone can be decreased when combined with Letermovir.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Drospirenone.]
[N01BX04, capsaicin, The metabolism of Drospirenone can be decreased when combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Drospirenone.]
[R06AX18, acrivastine, Drospirenone may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA01, captopril, Captopril may increase the hyperkalemic activities of Drospirenone.]
[L02BB05, apalutamide, The metabolism of Drospirenone can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Drospirenone can be decreased when it is combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The risk or severity of adverse effects can be increased when Drospirenone is combined with Calcium polycarbophil.]
[J01CA03, carbenicillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Carbenicillin.]
[C07AG02, carvedilol, The risk or severity of hyperkalemia can be increased when Carvedilol is combined with Drospirenone.]
[B02BX09, fostamatinib, The metabolism of Drospirenone can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Drospirenone can be increased when combined with Cannabidiol.]
[L04AA37, baricitinib, Drospirenone may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD14, ceftibuten, Drospirenone may increase the excretion rate of Ceftibuten which could result in a lower serum level and potentially a reduction in efficacy.]
[J01GB14, plazomicin, Drospirenone may increase the excretion rate of Plazomicin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB08, celiprolol, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Drospirenone can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Drospirenone may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, The metabolism of Drospirenone can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Drospirenone can be increased when combined with Tecovirimat.]
[J01AA13, eravacycline, The serum concentration of Drospirenone can be decreased when it is combined with Eravacycline.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Drospirenone.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Drospirenone.]
[J01AA14, sarecycline, The serum concentration of Drospirenone can be decreased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Drospirenone can be decreased when it is combined with Omadacycline.]
[S01GX12, cetirizine, Drospirenone may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Drospirenone.]
[D08AE05, chloroxylenol, Drospirenone may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC05, lornoxicam, The risk or severity of hyperkalemia can be increased when Lornoxicam is combined with Drospirenone.]
[L01ED05, lorlatinib, The metabolism of Drospirenone can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Drospirenone can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Drospirenone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be decreased when combined with Drospirenone.]
[A06AX05, prucalopride, The serum concentration of Drospirenone can be decreased when it is combined with Prucalopride.]
[C09AA08, cilazapril, Cilazapril may increase the hyperkalemic activities of Drospirenone.]
[B01AC23, cilostazol, Drospirenone may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.]
[P02BX04, triclabendazole, The metabolism of Drospirenone can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Drospirenone can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Drospirenone.]
[J01FA09, clarithromycin, The metabolism of Drospirenone can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Drospirenone may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX29, brexanolone, The metabolism of Drospirenone can be increased when combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Drospirenone.]
[N05BA09, clobazam, The serum concentration of Drospirenone can be decreased when it is combined with Clobazam.]
[J01AA11, clomocycline, The serum concentration of Drospirenone can be decreased when it is combined with Clomocycline.]
[H02AB14, cloprednol, The serum concentration of Cloprednol can be increased when it is combined with Drospirenone.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Drospirenone is combined with Castor oil.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Candesartan is combined with Drospirenone.]
[L04AB01, etanercept, The metabolism of Drospirenone can be increased when combined with Etanercept.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Drospirenone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The serum concentration of Cortivazol can be increased when it is combined with Drospirenone.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Drospirenone.]
[J01DC04, cefaclor, Drospirenone may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB05, cefadroxil, Drospirenone may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CF03, methicillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Meticillin.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Drospirenone.]
[J01DC05, cefotetan, Drospirenone may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD02, ceftazidime, Drospirenone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD04, ceftriaxone, Drospirenone may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Drospirenone.]
[N07XX11, pitolisant, The serum concentration of Drospirenone can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Drospirenone.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be decreased when combined with Drospirenone.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Drospirenone.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Drospirenone is combined with Dantron.]
[J01XX09, daptomycin, Drospirenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB01, cephalexin, Drospirenone may increase the excretion rate of Cephalexin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB09, cephradine, Drospirenone may increase the excretion rate of Cefradine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be increased when it is combined with Drospirenone.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Drospirenone.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Drospirenone.]
[N03AX25, cenobamate, The serum concentration of Drospirenone can be decreased when it is combined with Cenobamate.]
[M09AX08, golodirsen, Drospirenone may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA12, dexpanthenol, Drospirenone may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX03, dezocine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Dezocine.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Drospirenone.]
[J05AB16, remdesivir, The metabolism of Drospirenone can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Drospirenone can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Drospirenone can be decreased when combined with Amprenavir.]
[R02AA03, dichlorobenzyl alcohol, Drospirenone may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, Drospirenone may increase the excretion rate of Dienogest which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Dihydrocodeine.]
[M01AH02, rofecoxib, The risk or severity of hyperkalemia can be increased when Rofecoxib is combined with Drospirenone.]
[L01XF03, bexarotene, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Bexarotene.]
[C08CA16, clevidipine, Drospirenone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Drospirenone.]
[N03AG02, dipropylacetamide, The metabolism of Drospirenone can be increased when combined with Valpromide.]
[J01FA13, dirithromycin, The metabolism of Drospirenone can be decreased when combined with Dirithromycin.]
[S03AA08, chloramphenicol, The metabolism of Drospirenone can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Drospirenone.]
[D07XB03, fluprednidene, The serum concentration of Fluprednidene can be increased when it is combined with Drospirenone.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Droxicam is combined with Drospirenone.]
[V08CA05, mangafodipir, Drospirenone may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AE02, lepirudin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of hyperkalemia can be increased when Dexketoprofen is combined with Drospirenone.]
[N05CM02, chlormethiazole, The metabolism of Drospirenone can be increased when combined with Clomethiazole.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Drospirenone.]
[L04AC19, satralizumab, The serum concentration of Drospirenone can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, Drospirenone may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX23, pralsetinib, The metabolism of Drospirenone can be increased when combined with Pralsetinib.]
[N05AA01, chlorpromazine, Drospirenone may increase the excretion rate of Chlorpromazine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Drospirenone.]
[M03BB03, chlorzoxazone, Drospirenone may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Ethenzamide is combined with Drospirenone.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Drospirenone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA03, choline salicylate, Drospirenone may increase the excretion rate of Choline salicylate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX18, vinpocetine, The metabolism of Drospirenone can be increased when combined with Vinpocetine.]
[M01AB08, etodolac, The risk or severity of hyperkalemia can be increased when Etodolac is combined with Drospirenone.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Etofenamate is combined with Drospirenone.]
[B06AC06, berotralstat, The metabolism of Drospirenone can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Drospirenone can be decreased when combined with Lonafarnib.]
[M01AX25, chondroitin sulfates, Drospirenone may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AX07, abametapir, The serum concentration of Drospirenone can be increased when it is combined with Abametapir.]
[N03AX10, felbamate, The metabolism of Drospirenone can be increased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Fenbufen is combined with Drospirenone.]
[C01CA19, fenoldopam, Drospirenone may increase the excretion rate of Fenoldopam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD15, cefdinir, Drospirenone may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA03, flunisolide, The serum concentration of Flunisolide can be increased when it is combined with Drospirenone.]
[S02BA08, fluocinolone acetonide, The serum concentration of Fluocinolone acetonide can be increased when it is combined with Drospirenone.]
[N02BG07, flupirtine, Drospirenone may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Drospirenone.]
[A02BA01, cimetidine, Drospirenone may increase the excretion rate of Cimetidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF01, gabapentin, The metabolism of Drospirenone can be increased when combined with Gabapentin.]
[V08CA04, gadoteridol, Drospirenone may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA02, cinnarizine, The risk or severity of hyperkalemia can be increased when Cinnarizine is combined with Drospirenone.]
[L01XX73, sotorasib, The serum concentration of Drospirenone can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Drospirenone.]
[S03AA07, ciprofloxacin, The metabolism of Drospirenone can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Drospirenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB04, citalopram, The metabolism of Drospirenone can be decreased when combined with Citalopram.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Finerenone.]
[P01CA03, fexinidazole, The metabolism of Drospirenone can be decreased when combined with Fexinidazole.]
[L01XX74, belzutifan, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Drospirenone can be decreased when it is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Drospirenone may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AA01, technetium Tc 99m exametazime, Drospirenone may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX06, florbetaben f-18, Drospirenone may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA59, avacopan, The metabolism of Drospirenone can be decreased when combined with Avacopan.]
[M01AG01, mefenamic acid, The risk or severity of hyperkalemia can be increased when Mefenamic acid is combined with Drospirenone.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Drospirenone.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Drospirenone.]
[N06AX25, St. John's wort extract, The metabolism of Drospirenone can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Drospirenone can be decreased when combined with Asciminib.]
[J04BA01, clofazimine, The metabolism of Drospirenone can be decreased when combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of adverse effects can be increased when Drospirenone is combined with Tenecteplase.]
[C10AB01, clofibrate, The metabolism of Drospirenone can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Drospirenone can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, Drospirenone may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EJ03, pacritinib, The metabolism of Drospirenone can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Drospirenone.]
[N03AE01, clonazepam, The metabolism of Drospirenone can be increased when combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Drospirenone is combined with Clonidine.]
[C01EB24, mavacamten, The serum concentration of Drospirenone can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Drospirenone may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX16, tirzepatide, Tirzepatide can cause a decrease in the absorption of Drospirenone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01CF02, cloxacillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Cloxacillin.]
[N05AH02, clozapine, The metabolism of Drospirenone can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Drospirenone.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Drospirenone.]
[H01AC08, somatrogon, The metabolism of Drospirenone can be increased when combined with Somatrogon.]
[M09AX11, palovarotene, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Palovarotene.]
[L04AC21, bimekizumab, The metabolism of Drospirenone can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Proquazone is combined with Drospirenone.]
[R05DA04, codeine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Codeine.]
[J01CA18, hetacillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Hetacillin.]
[M04AC01, colchicine, Drospirenone may increase the excretion rate of Colchicine which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Drospirenone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A04AA03, tropisetron, Drospirenone may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX28, ifenprodil, The metabolism of Drospirenone can be increased when combined with Ifenprodil.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Drospirenone.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Imidazole salicylate is combined with Drospirenone.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Drospirenone.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Drospirenone.]
[J01FA15, telithromycin, The metabolism of Drospirenone can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The serum concentration of Ciclesonide can be increased when it is combined with Drospirenone.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Indobufen is combined with Drospirenone.]
[J05AB14, valganciclovir, Drospirenone may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Drospirenone may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Drospirenone may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Drospirenone may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Drospirenone may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Drospirenone may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Drospirenone.]
[N02CC05, almotriptan, Drospirenone may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH04, parecoxib, The risk or severity of hyperkalemia can be increased when Parecoxib is combined with Drospirenone.]
[J02AC02, itraconazole, The metabolism of Drospirenone can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Bemiparin.]
[S01AD03, acyclovir, Drospirenone may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA10, ketazolam, Drospirenone may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Kebuzone is combined with Drospirenone.]
[L01EA01, imatinib, The metabolism of Drospirenone can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Drospirenone can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Drospirenone is combined with Lactitol.]
[N03AX09, lamotrigine, The metabolism of Drospirenone can be increased when combined with Lamotrigine.]
[S01BA03, cortisone, The serum concentration of Cortisone can be increased when it is combined with Drospirenone.]
[N07BC04, lofexidine, Drospirenone may increase the excretion rate of Lofexidine which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Lonazolac is combined with Drospirenone.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Loxoprofen is combined with Drospirenone.]
[C09AA03, lisinopril, Lisinopril may increase the hyperkalemic activities of Drospirenone.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Drospirenone is combined with Magnesium carbonate.]
[C08CA11, manidipine, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Manidipine.]
[C07AA14, mepindolol, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Mepindolol.]
[H02AB15, meprednisone, The serum concentration of Meprednisone can be increased when it is combined with Drospirenone.]
[R06AD07, mequitazine, The metabolism of Drospirenone can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, Drospirenone may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA14, methampicillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Metampicillin.]
[C04AX01, cyclandelate, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Cyclandelate.]
[C03DA04, eplerenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Drospirenone.]
[N05AD03, metylperon, Drospirenone may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[J01FA03, midecamycin, The metabolism of Drospirenone can be decreased when combined with Midecamycin.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Drospirenone.]
[J05AF07, tenofovir disoproxil, Drospirenone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Drospirenone.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Drospirenone.]
[N06BA07, modafinil, The metabolism of Drospirenone can be increased when combined with Modafinil.]
[C09AA13, moexipril, Moexipril may increase the hyperkalemic activities of Drospirenone.]
[C10AA07, rosuvastatin, Rosuvastatin may decrease the excretion rate of Drospirenone which could result in a higher serum level.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Mofebutazone is combined with Drospirenone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Morniflumate is combined with Drospirenone.]
[C03XA02, conivaptan, The metabolism of Drospirenone can be decreased when combined with Conivaptan.]
[M01AH05, etoricoxib, The risk or severity of hyperkalemia can be increased when Etoricoxib is combined with Drospirenone.]
[L01AX04, dacarbazine, Drospirenone may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XA01, danazol, The metabolism of Drospirenone can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Drospirenone.]
[L01DB02, daunorubicin, The metabolism of Drospirenone can be decreased when combined with Daunorubicin.]
[M01AX01, nabumetone, The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Drospirenone.]
[N07BB05, nalmefene, Drospirenone may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of adverse effects can be increased when Drospirenone is combined with Potassium lactate.]
[J01AA01, demeclocycline, The serum concentration of Drospirenone can be decreased when it is combined with Demeclocycline.]
[C07AB12, nebivolol, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Nebivolol.]
[S01GX04, nedocromil, Drospirenone may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, The metabolism of Drospirenone can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Drospirenone may increase the excretion rate of Nicorandil which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BB02, nilutamide, Drospirenone may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AG06, tiagabine, The metabolism of Drospirenone can be increased when combined with Tiagabine.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Drospirenone.]
[R05DA06, normethadone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, The risk or severity of adverse effects can be increased when Drospirenone is combined with Fondaparinux.]
[A07EC03, olsalazine, The risk or severity of hyperkalemia can be increased when Olsalazine is combined with Drospirenone.]
[N06AA01, desipramine, Drospirenone may increase the excretion rate of Desipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[H01BA02, desmopressin, Drospirenone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XC02, desoximetasone, The serum concentration of Desoximetasone can be increased when it is combined with Drospirenone.]
[V04CH02, indigo carmine, Drospirenone may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA03, desoxycorticosterone, The serum concentration of Desoxycortone can be increased when it is combined with Drospirenone.]
[J01DH03, ertapenem, Drospirenone may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Drospirenone.]
[N03AF02, oxcarbazepine, The metabolism of Drospirenone can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The serum concentration of Dexamethasone can be increased when it is combined with Drospirenone.]
[G04BD04, oxybutynin, The metabolism of Drospirenone can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Drospirenone can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Drospirenone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AC01, paramethadione, The metabolism of Drospirenone can be increased when combined with Paramethadione.]
[N02AC01, dextromoramide, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Dextromoramide.]
[N07BC06, heroin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Drospirenone may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AC04, permethrin, Drospirenone may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, The metabolism of Drospirenone can be increased when combined with Diazepam.]
[N03AX07, phenacemide, The metabolism of Drospirenone can be increased when combined with Phenacemide.]
[J01CE05, phenethicillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Pheneticillin.]
[N03AD02, phensuximide, The metabolism of Drospirenone can be increased when combined with Phensuximide.]
[R05DA08, pholcodine, Drospirenone may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Drospirenone.]
[J01CF01, dicloxacillin, The metabolism of Drospirenone can be increased when combined with Dicloxacillin.]
[A03AA07, dicyclomine, Drospirenone may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF02, didanosine, Drospirenone may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AX04, pinaverium, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Pinaverium.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Drospirenone.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Drospirenone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Drospirenone.]
[L02AA01, diethylstilbestrol, The metabolism of Drospirenone can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Drospirenone can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The serum concentration of Difluocortolone can be increased when it is combined with Drospirenone.]
[N02BA11, diflunisal, The risk or severity of hyperkalemia can be increased when Diflunisal is combined with Drospirenone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Drospirenone.]
[C01AA05, digoxin, Drospirenone may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Drospirenone.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Drospirenone.]
[N02AA03, hydromorphone, Drospirenone may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Drospirenone may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE08, atazanavir, The serum concentration of Drospirenone can be increased when it is combined with Atazanavir.]
[H03BC01, potassium perchlorate, Drospirenone may increase the excretion rate of Potassium perchlorate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB04, pralidoxime, Drospirenone may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DB01, diltiazem, The metabolism of Drospirenone can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, Drospirenone may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AX03, dimethyl sulfoxide, Drospirenone may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AG05, progabide, The metabolism of Drospirenone can be increased when combined with Progabide.]
[J01CE03, propicillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Propicillin.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Propyphenazone is combined with Drospirenone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Proglumetacin is combined with Drospirenone.]
[C05CA03, diosmin, The metabolism of Drospirenone can be decreased when combined with Diosmin.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Diphenoxylate.]
[C09AA06, quinapril, Quinapril may increase the hyperkalemic activities of Drospirenone.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Drospirenone is combined with Dipyridamole.]
[B01AD10, drotrecogin alfa, The risk or severity of adverse effects can be increased when Drospirenone is combined with Drotrecogin alfa.]
[A03FA02, cisapride, The metabolism of Drospirenone can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Ramipril may increase the hyperkalemic activities of Drospirenone.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Drospirenone.]
[S01AX06, resorcinol, Drospirenone may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Drospirenone.]
[S02AA12, rifamycin SV, The metabolism of Drospirenone can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Drospirenone can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The metabolism of Drospirenone can be increased when combined with Riluzole.]
[R06AE09, levocetirizine, Drospirenone may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB09, ropivacaine, Drospirenone may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Drospirenone.]
[A04AD12, aprepitant, The serum concentration of Drospirenone can be decreased when it is combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Drospirenone.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Drospirenone.]
[J05AE07, fosamprenavir, The metabolism of Drospirenone can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, Drospirenone may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC05, ketorolac, The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Drospirenone.]
[C01EB18, ranolazine, Drospirenone may increase the excretion rate of Ranolazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Salsalate is combined with Drospirenone.]
[H05BA01, salmon calcitonin, Drospirenone may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, Drospirenone may increase the excretion rate of Dobutamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA04, dopamine, Drospirenone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA12, doxepin, Drospirenone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Drospirenone is combined with Sennosides.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Drospirenone.]
[J01AA02, doxycycline, The serum concentration of Drospirenone can be decreased when it is combined with Doxycycline.]
[A08AA10, sibutramine, Drospirenone may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AG05, sodium phosphate, Drospirenone may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Drospirenone is combined with Sodium sulfate.]
[C09AA11, spirapril, Spirapril may increase the hyperkalemic activities of Drospirenone.]
[R03DA01, dyphylline, Drospirenone may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC01, sumatriptan, Drospirenone may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX07, edrophonium, Drospirenone may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Talinolol.]
[H01AA01, corticotropin, The serum concentration of Corticotropin can be increased when it is combined with Drospirenone.]
[J01CA17, temocillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Temocillin.]
[L01AX03, temozolomide, Drospirenone may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The risk or severity of hyperkalemia can be increased when Tenoxicam is combined with Drospirenone.]
[D01BA02, terbinafine, The metabolism of Drospirenone can be increased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Terodiline.]
[C07AA16, tertatolol, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Tertatolol.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Drospirenone.]
[C09AA02, enalapril, Enalapril may increase the hyperkalemic activities of Drospirenone.]
[M01AG02, tolfenamic acid, The risk or severity of hyperkalemia can be increased when Tolfenamic acid is combined with Drospirenone.]
[N06AG03, toloxatone, Drospirenone may increase the excretion rate of Toloxatone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA09, atomoxetine, Drospirenone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX11, topiramate, The metabolism of Drospirenone can be increased when combined with Topiramate.]
[J01AA12, tigecycline, The serum concentration of Drospirenone can be decreased when it is combined with Tigecycline.]
[C09AA10, trandolapril, Trandolapril may increase the hyperkalemic activities of Drospirenone.]
[N05CC01, chloral hydrate, Drospirenone may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC18, triflusal, The risk or severity of adverse effects can be increased when Drospirenone is combined with Triflusal.]
[H02CA01, trilostane, The serum concentration of Trilostane can be increased when it is combined with Drospirenone.]
[C05CA04, troxerutin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Troxerutin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Drospirenone.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Drospirenone.]
[N06AX16, venlafaxine, Drospirenone may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA12, mepirodipine, The metabolism of Drospirenone can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Drospirenone can be decreased when combined with Epinephrine.]
[C09AA15, zofenopril, Zofenopril may increase the hyperkalemic activities of Drospirenone.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Zomepirac is combined with Drospirenone.]
[N03AX15, zonisamide, The metabolism of Drospirenone can be increased when combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Drospirenone.]
[B01AD03, anistreplase, The risk or severity of adverse effects can be increased when Drospirenone is combined with Anistreplase.]
[L01XA02, carboplatin, Drospirenone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC02, guanfacine, Drospirenone may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA02, ergotamine, The metabolism of Drospirenone can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Drospirenone may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA17, erythromycin, The metabolism of Drospirenone can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The metabolism of Drospirenone can be increased when combined with Estazolam.]
[A02BC02, pantoprazole, Drospirenone may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA57, estrogens, conjugated (USP), Drospirenone may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, Drospirenone may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA09, fluticasone furoate, The serum concentration of Fluticasone furoate can be increased when it is combined with Drospirenone.]
[R03BA05, fluticasone, The serum concentration of Fluticasone can be increased when it is combined with Drospirenone.]
[V08CA03, gadodiamide, Drospirenone may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD05, ibutilide, Drospirenone may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD01, ethosuximide, The metabolism of Drospirenone can be increased when combined with Ethosuximide.]
[N03AB01, ethotoin, The metabolism of Drospirenone can be increased when combined with Ethotoin.]
[M01AC06, meloxicam, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Drospirenone.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Ethylmorphine.]
[N01AX07, etomidate, Drospirenone may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Drospirenone.]
[D05BB01, etretinate, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Etretinate.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be decreased when combined with Drospirenone.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Drospirenone.]
[R06AX12, terfenadine, The metabolism of Drospirenone can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Drospirenone may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, Drospirenone may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB08, fluvoxamine, The metabolism of Drospirenone can be decreased when combined with Fluvoxamine.]
[L02AE02, leuprolide, Drospirenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01CB01, gold sodium thiomalate, Drospirenone may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[A05AA01, chenodeoxycholic acid, The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Drospirenone.]
[D11AX24, deoxycholic acid, The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Drospirenone.]
[B05AA05, dextran, The risk or severity of adverse effects can be increased when Drospirenone is combined with Dextran.]
[V03AF02, dexrazoxane, Drospirenone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA01, levocarnitine, Drospirenone may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA03, albendazole, The metabolism of Drospirenone can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of hyperkalemia can be increased when Felodipine is combined with Drospirenone.]
[C08EA01, fendiline, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Fendiline.]
[N03AX26, fenfluramine, The metabolism of Drospirenone can be increased when combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Drospirenone.]
[N02AB03, fentanyl, Drospirenone may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, Drospirenone may increase the excretion rate of Salbutamol which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AD05, plasmin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Fibrinolysin.]
[L01BB06, clofarabine, Drospirenone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07AX03, cevimeline, Drospirenone may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Drospirenone may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Floctafenine is combined with Drospirenone.]
[J01CF05, floxacillin, The metabolism of Drospirenone can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The bioavailability of Drospirenone can be increased when combined with Fluconazole.]
[J02AX01, flucytosine, Drospirenone may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA02, fludrocortisone, The serum concentration of Fludrocortisone can be increased when it is combined with Drospirenone.]
[V03AB25, flumazenil, Drospirenone may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XB01, flumethasone, The serum concentration of Flumethasone can be increased when it is combined with Drospirenone.]
[N07CA03, flunarizine, The metabolism of Drospirenone can be increased when combined with Flunarizine.]
[D07AC08, fluocinonide, The serum concentration of Fluocinonide can be increased when it is combined with Drospirenone.]
[H02AB03, fluocortolone, The serum concentration of Fluocortolone can be increased when it is combined with Drospirenone.]
[V03AZ01, ethanol, The metabolism of Drospirenone can be increased when combined with Ethanol.]
[L01BC09, floxuridine, Drospirenone may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01CB05, fluorometholone, The serum concentration of Fluorometholone can be increased when it is combined with Drospirenone.]
[N06AB03, fluoxetine, The metabolism of Drospirenone can be decreased when combined with Fluoxetine.]
[N05CD01, flurazepam, Drospirenone may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, The risk or severity of hyperkalemia can be increased when Flurbiprofen is combined with Drospirenone.]
[N05AG01, fluspirilene, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Fluspirilene.]
[L02BB01, flutamide, Drospirenone may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Drospirenone may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Drospirenone may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC03, tegafur, Drospirenone may increase the excretion rate of Tegafur which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE10, darunavir, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Darunavir.]
[C03CA01, furosemide, Drospirenone may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Drospirenone may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DA02, gallopamil, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Gallopamil.]
[S01AD09, ganciclovir, Drospirenone may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, The metabolism of Drospirenone can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, Drospirenone may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XA03, telavancin, Drospirenone may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Drospirenone.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Drospirenone.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Drospirenone.]
[J05AG04, etravirine, The metabolism of Drospirenone can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The metabolism of Drospirenone can be increased when combined with Methsuximide.]
[N01AH02, alfentanil, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Drospirenone can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Drospirenone.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Drospirenone.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Drospirenone.]
[N05CM18, dexmedetomidine, Drospirenone may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Glycerin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Drospirenone.]
[C02CA04, doxazosin, The metabolism of Drospirenone can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Drospirenone.]
[C07AB09, esmolol, The risk or severity of hyperkalemia can be increased when Esmolol is combined with Drospirenone.]
[M01CB04, aurothioglucose, Drospirenone may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Drospirenone may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Drospirenone is combined with Fluindione.]
[C09AA09, fosinopril, Fosinopril may increase the hyperkalemic activities of Drospirenone.]
[D01BA01, griseofulvin, The metabolism of Drospirenone can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Drospirenone may increase the excretion rate of Guanethidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE03, goserelin, Drospirenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Drospirenone.]
[N05AH04, quetiapine, Drospirenone may increase the excretion rate of Quetiapine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX13, idebenone, Drospirenone may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Drospirenone.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Drospirenone.]
[M04AA01, allopurinol, Drospirenone may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA01, losartan, The risk or severity of hyperkalemia can be increased when Losartan is combined with Drospirenone.]
[S01XA14, heparin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Heparin.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Drospirenone is combined with Magnesium citrate.]
[G03DC01, allylestrenol, Drospirenone may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC02, mesalamine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Drospirenone.]
[C01CE02, milrinone, Drospirenone may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Drospirenone is combined with Sodium fluorophosphate.]
[N05CA16, hexobarbital, The metabolism of Drospirenone can be increased when combined with Hexobarbital.]
[C08CA10, nilvadipine, The metabolism of Drospirenone can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hyperkalemia can be increased when Nimesulide is combined with Drospirenone.]
[C09AA04, perindopril, Perindopril may increase the hyperkalemic activities of Drospirenone.]
[C02DB02, hydralazine, Drospirenone may increase the excretion rate of Hydralazine which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA03, hydrocodone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Hydrocodone.]
[S02BA01, hydrocortisone, The serum concentration of Hydrocortisone can be increased when it is combined with Drospirenone.]
[B05XA17, potassium acetate, Drospirenone may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Drospirenone.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Drospirenone.]
[V03AB33, hydroxocobalamin, Drospirenone may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Drospirenone may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA07, hetastarch, Drospirenone may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AB04, rifabutin, The metabolism of Drospirenone can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Drospirenone.]
[B05XA08, sodium acetate, Drospirenone may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05CB02, sodium citrate, The risk or severity of adverse effects can be increased when Drospirenone is combined with Sodium citrate.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Drospirenone is combined with Sodium tartrate.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Drospirenone.]
[N01AH03, sufentanil, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, Drospirenone may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Drospirenone.]
[R01AD07, tixocortol, The serum concentration of Tixocortol can be increased when it is combined with Drospirenone.]
[M03BX02, tizanidine, The metabolism of Drospirenone can be increased when combined with Tizanidine.]
[L01CE01, topotecan, Drospirenone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, Drospirenone may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Drospirenone.]
[A11HA07, inositol, Drospirenone may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, The metabolism of Drospirenone can be decreased when combined with Milnacipran.]
[S01XA28, varenicline, Drospirenone may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Drospirenone.]
[N05BA12, alprazolam, Drospirenone may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Drospirenone may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Drospirenone.]
[C10AA06, cerivastatin, The metabolism of Drospirenone can be increased when combined with Cerivastatin.]
[C07AA01, alprenolol, The risk or severity of hyperkalemia can be increased when Alprenolol is combined with Drospirenone.]
[V03AB01, ipecac, Drospirenone may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA16, imidapril, Imidapril may increase the hyperkalemic activities of Drospirenone.]
[J04AC01, isoniazid, The metabolism of Drospirenone can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Drospirenone may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ01, exenatide, Exenatide can cause a decrease in the absorption of Drospirenone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01DA14, isosorbide mononitrate, Drospirenone may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[D10BA01, isotretinoin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Isotretinoin.]
[B01AE06, bivalirudin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Bivalirudin.]
[L04AC07, tocilizumab, The metabolism of Drospirenone can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Drospirenone may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC22, prasugrel, The risk or severity of adverse effects can be increased when Drospirenone is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Drospirenone can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Drospirenone can be decreased when combined with Levoketoconazole.]
[M02AA10, ketoprofen, The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Drospirenone.]
[V03AC03, deferasirox, The metabolism of Drospirenone can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Drospirenone can be increased when combined with Abatacept.]
[D10AX03, azelaic acid, Drospirenone may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Tiaprofenic acid is combined with Drospirenone.]
[C07AG01, labetalol, Drospirenone may increase the excretion rate of Labetalol which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BB01, amantadine, Drospirenone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Drospirenone is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Drospirenone is combined with Lubiprostone.]
[N03AX18, lacosamide, The metabolism of Drospirenone can be increased when combined with Lacosamide.]
[J01CA11, amdinocillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Amdinocillin.]
[J01CA08, amdinocillin pivoxil, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Pivmecillinam.]
[C08EX01, lidoflazine, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Drospirenone can be increased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Amiloride is combined with Drospirenone.]
[A07DA03, loperamide, The risk or severity of hyperkalemia can be increased when Loperamide is combined with Drospirenone.]
[N05BA06, lorazepam, The metabolism of Drospirenone can be increased when combined with Lorazepam.]
[C10AA02, lovastatin, The metabolism of Drospirenone can be decreased when combined with Lovastatin.]
[J01AA04, lymecycline, The serum concentration of Drospirenone can be decreased when it is combined with Lymecycline.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Drospirenone.]
[B05XA11, magnesium chloride, Drospirenone may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Drospirenone is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Drospirenone is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The metabolism of Drospirenone can be increased when combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Drospirenone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA03, nilotinib, The metabolism of Drospirenone can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Drospirenone is combined with Mannitol.]
[N06AA21, maprotiline, Drospirenone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BB01, mecamylamine, Drospirenone may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA18, meclofenamic acid, The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Drospirenone.]
[N05BA03, medazepam, The metabolism of Drospirenone can be increased when combined with Medazepam.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Drospirenone is combined with Frangula purshiana bark.]
[B01AB06, nadroparin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Dalteparin.]
[N06DX01, memantine, Drospirenone may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, Drospirenone may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AB04, mephenytoin, The metabolism of Drospirenone can be increased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Drospirenone can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, Drospirenone may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Drospirenone may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BG01, aminoglutethimide, The metabolism of Drospirenone can be increased when combined with Aminoglutethimide.]
[C03BC01, mersalyl, Drospirenone may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Drospirenone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Drospirenone.]
[H01CB03, lanreotide, The metabolism of Drospirenone can be decreased when combined with Lanreotide.]
[J01AA05, methacycline, The serum concentration of Drospirenone can be decreased when it is combined with Metacycline.]
[N07BC02, methadone, Drospirenone may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA03, methamphetamine, Drospirenone may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF05, lamivudine, Drospirenone may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA30, metharbital, The metabolism of Drospirenone can be increased when combined with Metharbital.]
[H03BB02, methimazole, The metabolism of Drospirenone can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Drospirenone may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA15, methohexital, The metabolism of Drospirenone can be increased when combined with Methohexital.]
[A11HA02, pyridoxine, Drospirenone may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Drospirenone is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Drospirenone.]
[D05BA02, methoxsalen, Drospirenone may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Drospirenone is combined with Methylcellulose.]
[C02AB01, methyldopa, Drospirenone may increase the excretion rate of Methyldopa which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CG05, methylene blue, Drospirenone may increase the excretion rate of Methylene blue which could result in a lower serum level and potentially a reduction in efficacy.]
[G02AB01, methylergonovine, The metabolism of Drospirenone can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Drospirenone.]
[H02AB04, methylprednisolone, The serum concentration of Methylprednisolone can be increased when it is combined with Drospirenone.]
[D07AC14, methylprednisolone aceponate, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Drospirenone.]
[N03AF03, rufinamide, The metabolism of Drospirenone can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, Drospirenone may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA04, methysergide, The metabolism of Drospirenone can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, Drospirenone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, Drospirenone may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Drospirenone may increase the excretion rate of Metoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01AB01, metronidazole, The metabolism of Drospirenone can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, Drospirenone may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA10, mezlocillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Mezlocillin.]
[S02AA13, miconazole, The metabolism of Drospirenone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hyperkalemia can be increased when Aminophenazone is combined with Drospirenone.]
[B01AB07, parnaparin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Parnaparin.]
[N05CD08, midazolam, Drospirenone may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Drospirenone.]
[B01AB10, tinzaparin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Tinzaparin.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Drospirenone is combined with Mineral oil.]
[J05AH01, zanamivir, Drospirenone may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Drospirenone.]
[J01AA08, minocycline, The serum concentration of Drospirenone can be decreased when it is combined with Minocycline.]
[J01FA11, miocamycin, The metabolism of Drospirenone can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Drospirenone can be increased when combined with Mitotane.]
[L03AC01, aldesleukin, Drospirenone may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD01, amiodarone, The metabolism of Drospirenone can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Drospirenone may increase the excretion rate of Amitriptyline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA01, morphine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Morphine.]
[A04AA05, palonosetron, Drospirenone may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB05, certolizumab pegol, The metabolism of Drospirenone can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Drospirenone may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Drospirenone.]
[L04AA06, mycophenolic acid, The serum concentration of Drospirenone can be decreased when it is combined with Mycophenolic acid.]
[N05CA02, amobarbital, The metabolism of Drospirenone can be increased when combined with Amobarbital.]
[G03XC01, raloxifene, The metabolism of Drospirenone can be decreased when combined with Raloxifene.]
[N03AB05, fosphenytoin, The metabolism of Drospirenone can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Drospirenone may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA04, amoxicillin, Drospirenone may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CF06, nafcillin, The metabolism of Drospirenone can be increased when combined with Nafcillin.]
[N02AF02, nalbuphine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Drospirenone can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Naltrexone.]
[L04AC03, anakinra, The metabolism of Drospirenone can be increased when combined with Anakinra.]
[N06BA01, amphetamine, Drospirenone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The risk or severity of hyperkalemia can be increased when Naproxen is combined with Drospirenone.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Drospirenone.]
[N06AX21, duloxetine, Drospirenone may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BX01, tolcapone, Drospirenone may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Drospirenone.]
[N01AH06, remifentanil, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Remifentanil.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Drospirenone.]
[B01AC17, tirofiban, Drospirenone may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA19, ampicillin, Drospirenone may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Drospirenone may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX23, desvenlafaxine, The metabolism of Drospirenone can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Drospirenone.]
[J05AB11, valacyclovir, Drospirenone may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CE01, inamrinone, Drospirenone may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AD02, niacin, The metabolism of Drospirenone can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Drospirenone can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, Drospirenone may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA17, niflumic acid, The risk or severity of hyperkalemia can be increased when Niflumic acid is combined with Drospirenone.]
[C08CA06, nimodipine, The risk or severity of hyperkalemia can be increased when Nimodipine is combined with Drospirenone.]
[C08CA07, nisoldipine, Drospirenone may increase the excretion rate of Nisoldipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD02, nitrazepam, The metabolism of Drospirenone can be increased when combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of hyperkalemia can be increased when Nitrendipine is combined with Drospirenone.]
[R07AX01, nitric oxide, Drospirenone may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Drospirenone may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF03, zaleplon, The metabolism of Drospirenone can be increased when combined with Zaleplon.]
[N04BC05, pramipexole, Drospirenone may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, Drospirenone may increase the excretion rate of Nitroprusside which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA03, norepinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Drospirenone.]
[G03DC02, norethindrone, The metabolism of Drospirenone can be decreased when combined with Norethisterone.]
[C02KX01, bosentan, The serum concentration of Drospirenone can be decreased when it is combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Drospirenone.]
[R05DA07, noscapine, The metabolism of Drospirenone can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Nylidrin.]
[B01AB08, reviparin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Reviparin.]
[H01CB02, octreotide, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Octreotide.]
[J01FA05, oleandomycin, The metabolism of Drospirenone can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Drospirenone can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Drospirenone can be increased when combined with Omeprazole.]
[N02AA02, opium, Drospirenone may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AD07, reteplase, The risk or severity of adverse effects can be increased when Drospirenone is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of adverse effects can be increased when Drospirenone is combined with Ancrod.]
[G04CA02, tamsulosin, Drospirenone may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CF04, oxacillin, Drospirenone may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA04, oxazepam, Drospirenone may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA02, oxprenolol, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Oxycodone.]
[N02AA11, oxymorphone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Oxymorphone.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Oxyphenbutazone is combined with Drospirenone.]
[S01AA04, oxytetracycline, The serum concentration of Drospirenone can be decreased when it is combined with Oxytetracycline.]
[B01AB09, danaparoid, The risk or severity of adverse effects can be increased when Drospirenone is combined with Danaparoid.]
[N02AX06, tapentadol, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Tapentadol.]
[J04AB30, capreomycin, Drospirenone may increase the excretion rate of Capreomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC05, paraldehyde, The metabolism of Drospirenone can be increased when combined with Paraldehyde.]
[H02AB05, paramethasone, The serum concentration of Paramethasone can be increased when it is combined with Drospirenone.]
[G04BD11, fesoterodine, Drospirenone may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, Drospirenone may increase the excretion rate of Penbutolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AG03, penfluridol, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Penfluridol.]
[S01AA14, penicillin G, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Benzylpenicillin.]
[J01CE09, penicillin G procaine, Drospirenone may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CE02, penicillin V, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Phenoxymethylpenicillin.]
[N02AD01, pentazocine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Drospirenone can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Drospirenone may increase the excretion rate of Pentostatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AD03, pentoxifylline, Drospirenone may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C08EX02, perhexiline, The risk or severity of hyperkalemia can be increased when Perhexiline is combined with Drospirenone.]
[N02AD02, phenazocine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, Drospirenone may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF03, phenelzine, Drospirenone may increase the excretion rate of Phenelzine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Drospirenone.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Drospirenone is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Drospirenone can be increased when combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Drospirenone is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Phenoperidine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Drospirenone is combined with Phenprocoumon.]
[V03AB36, phentolamine, Drospirenone may increase the excretion rate of Phentolamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA01, phenylbutazone, The risk or severity of hyperkalemia can be increased when Phenylbutazone is combined with Drospirenone.]
[N03AB02, phenytoin, The metabolism of Drospirenone can be increased when combined with Phenytoin.]
[L01XF02, alitretinoin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Alitretinoin.]
[L04AB06, golimumab, The metabolism of Drospirenone can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Drospirenone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Drospirenone.]
[B02BA01, vitamin K1, Drospirenone may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, Drospirenone may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CX01, mibefradil, The metabolism of Drospirenone can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Drospirenone.]
[C07AA03, pindolol, Drospirenone may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA12, piperacillin, Drospirenone may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE01, saquinavir, The metabolism of Drospirenone can be decreased when combined with Saquinavir.]
[N06BX03, piracetam, Drospirenone may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Drospirenone.]
[N02AC03, pirinitramide, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hyperkalemia can be increased when Piroxicam is combined with Drospirenone.]
[J01CA02, pivampicillin, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Pivampicillin.]
[J05AG02, delavirdine, The metabolism of Drospirenone can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Drospirenone.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Drospirenone is combined with Abciximab.]
[D05AX05, tazarotene, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Tazarotene.]
[S01XA13, alteplase, The risk or severity of adverse effects can be increased when Drospirenone is combined with Alteplase.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Drospirenone.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Drospirenone is combined with Polyethylene glycol.]
[L04AC08, canakinumab, The metabolism of Drospirenone can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Drospirenone can be decreased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Drospirenone.]
[B05XA01, potassium chloride, Drospirenone may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Drospirenone.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Drospirenone.]
[C07AB01, practolol, The risk or severity of hyperkalemia can be increased when Practolol is combined with Drospirenone.]
[S03BA02, prednisolone, The serum concentration of Prednisolone can be increased when it is combined with Drospirenone.]
[H02AB07, prednisone, The serum concentration of Prednisone can be increased when it is combined with Drospirenone.]
[C01DX02, prenylamine, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Drospirenone can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Drospirenone can be increased when combined with Primidone.]
[M04AB01, probenecid, Drospirenone may increase the excretion rate of Probenecid which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA02, procainamide, Drospirenone may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AB05, fenofibrate, Drospirenone may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD02, promethazine, Drospirenone may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BC03, propafenone, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Drospirenone.]
[A03AB05, propantheline, Drospirenone may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Drospirenone.]
[N01AX10, propofol, The metabolism of Drospirenone can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Drospirenone can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Drospirenone may increase the excretion rate of Propranolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC04, rizatriptan, Drospirenone may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Drospirenone is combined with Epoprostenol.]
[N07XX07, dalfampridine, Drospirenone may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CC01, pyrantel, Drospirenone may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK01, pyrazinamide, Drospirenone may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Drospirenone.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Drospirenone.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Drospirenone.]
[A02BA02, ranitidine, Drospirenone may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, Rescinnamine may increase the hyperkalemic activities of Drospirenone.]
[C02AA02, reserpine, Drospirenone may increase the excretion rate of Reserpine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP01, ribavirin, Drospirenone may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AB02, rifampin, The metabolism of Drospirenone can be increased when combined with Rifampicin.]
[J01AA09, rolitetracycline, The serum concentration of Drospirenone can be decreased when it is combined with Rolitetracycline.]
[J01FA06, roxithromycin, The metabolism of Drospirenone can be decreased when combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Salicylamide is combined with Drospirenone.]
[A07EC01, sulfasalazine, The risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Drospirenone.]
[S01BC08, salicylic acid, The risk or severity of hyperkalemia can be increased when Salicylic acid is combined with Drospirenone.]
[N05CA06, secobarbital, The metabolism of Drospirenone can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The bioavailability of Selegiline can be increased when combined with Drospirenone.]
[A12CD01, sodium fluoride, Drospirenone may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[H01CB01, somatostatin, The metabolism of Drospirenone can be decreased when combined with Somatostatin.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Drospirenone is combined with Sorbitol.]
[C07AA07, sotalol, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Drospirenone.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Drospirenone.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Drospirenone.]
[N03AG01, valproic acid, The metabolism of Drospirenone can be increased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The serum concentration of Hydrocortisone butyrate can be increased when it is combined with Drospirenone.]
[A05AA02, ursodiol, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Drospirenone.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Ethinylestradiol.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Streptokinase.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, Ethinylestradiol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).]
[J01CA16, sulbenicillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Sulbenicillin.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Ethinylestradiol.]
[S01AB01, sulfamethizole, The metabolism of Ethinylestradiol can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, Ethinylestradiol may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01EC03, sulfamoxole, The metabolism of Ethinylestradiol can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Ethinylestradiol can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, Ethinylestradiol may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Ethinylestradiol.]
[N03AX03, sulthiame, The metabolism of Ethinylestradiol can be increased when combined with Sulthiame.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Ethinylestradiol.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Ethinylestradiol.]
[N06DA01, tacrine, The metabolism of Ethinylestradiol can be decreased when combined with Tacrine.]
[J01CA15, talampicillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Talampicillin.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Ethinylestradiol.]
[N05CD07, temazepam, Ethinylestradiol may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Ethinylestradiol.]
[B01AE07, dabigatran etexilate, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Ethinylestradiol can be increased when combined with Testosterone.]
[S03AA02, tetracycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Tetracycline.]
[A04AD10, dronabinol, The metabolism of Ethinylestradiol can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Ethinylestradiol.]
[L04AX02, thalidomide, Ethinylestradiol may increase the thrombogenic activities of Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Ethinylestradiol.]
[R03DA04, theophylline, Ethinylestradiol may decrease the excretion rate of Theophylline which could result in a higher serum level.]
[P02CA02, thiabendazole, The metabolism of Ethinylestradiol can be decreased when combined with Thiabendazole.]
[N05CA19, thiopental, The metabolism of Ethinylestradiol can be increased when combined with Thiopental.]
[N05AC02, thioridazine, The metabolism of Thioridazine can be decreased when combined with Ethinylestradiol.]
[N05AF04, thiothixene, The metabolism of Thiothixene can be decreased when combined with Ethinylestradiol.]
[J01CA13, ticarcillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Ticarcillin.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Ethinylestradiol.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Ethinylestradiol.]
[P01AB02, tinidazole, Ethinylestradiol may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Ethinylestradiol.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ethinylestradiol.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Ethinylestradiol.]
[B02AA02, tranexamic acid, Ethinylestradiol may increase the thrombogenic activities of Tranexamic acid.]
[N06AF04, tranylcypromine, The metabolism of Ethinylestradiol can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The metabolism of Ethinylestradiol can be decreased when combined with Trazodone.]
[L01XF01, tretinoin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Triamcinolone can be decreased when combined with Ethinylestradiol.]
[C03DB02, triamterene, The metabolism of Ethinylestradiol can be decreased when combined with Triamterene.]
[N05CD05, triazolam, The metabolism of Ethinylestradiol can be decreased when combined with Triazolam.]
[N05AB06, trifluoperazine, The metabolism of Ethinylestradiol can be decreased when combined with Trifluoperazine.]
[S01AD02, trifluridine, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Trifluridine.]
[D07AC02, fluclorolone, The serum concentration of Fluclorolone can be increased when it is combined with Ethinylestradiol.]
[R03BA07, mometasone, The serum concentration of Mometasone can be increased when it is combined with Ethinylestradiol.]
[N03AC02, trimethadione, The metabolism of Ethinylestradiol can be increased when combined with Trimethadione.]
[J01EA01, trimethoprim, The metabolism of Ethinylestradiol can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Ethinylestradiol.]
[J01FA08, troleandomycin, The metabolism of Ethinylestradiol can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Ethinylestradiol.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Ethinylestradiol.]
[L04AA26, belimumab, Ethinylestradiol may increase the thrombogenic activities of Belimumab.]
[L01FX04, ipilimumab, Ethinylestradiol may increase the thrombogenic activities of Ipilimumab.]
[L02BX03, abiraterone, The serum concentration of Ethinylestradiol can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ethinylestradiol.]
[J05AP03, boceprevir, The serum concentration of Ethinylestradiol can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Ethinylestradiol can be decreased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Ethinylestradiol can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Urokinase.]
[N03AX21, ezogabine, The metabolism of Ethinylestradiol can be increased when combined with Ezogabine.]
[B01AF01, rivaroxaban, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Rivaroxaban.]
[R03AC18, indacaterol, The metabolism of Indacaterol can be increased when combined with Ethinylestradiol.]
[B01AC24, ticagrelor, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Ethinylestradiol can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Ethinylestradiol can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, Ethinylestradiol may decrease the excretion rate of Vinblastine which could result in a higher serum level.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Ethinylestradiol.]
[S01XA02, vitamin A, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Vitamin A.]
[A11HA03, vitamin E, The metabolism of Ethinylestradiol can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Warfarin.]
[J05AF01, zidovudine, The metabolism of Ethinylestradiol can be increased when combined with Zidovudine.]
[J05AE02, indinavir, The metabolism of Ethinylestradiol can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The metabolism of Ethinylestradiol can be increased when combined with Levetiracetam.]
[L01EC01, vemurafenib, The serum concentration of Ethinylestradiol can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, Ethinylestradiol may increase the thrombogenic activities of Brentuximab vedotin.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Ethinylestradiol.]
[B01AE01, desirudin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Ethinylestradiol can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Ethinylestradiol.]
[S01XA15, ascorbic acid, The serum concentration of Ascorbic acid can be decreased when it is combined with Ethinylestradiol.]
[J01MA13, trovafloxacin, The metabolism of Ethinylestradiol can be decreased when combined with Trovafloxacin.]
[N05AE04, ziprasidone, The metabolism of Ethinylestradiol can be decreased when combined with Ziprasidone.]
[L04AA34, alemtuzumab, Ethinylestradiol may increase the thrombogenic activities of Alemtuzumab.]
[N02BA01, aspirin, The metabolism of Ethinylestradiol can be decreased when combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Ethinylestradiol.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Ethinylestradiol.]
[C07AB03, atenolol, Ethinylestradiol may decrease the excretion rate of Atenolol which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The metabolism of Ethinylestradiol can be decreased when combined with Peginterferon alfa-2a.]
[L01FA01, rituximab, Ethinylestradiol may increase the thrombogenic activities of Rituximab.]
[J02AC03, voriconazole, The serum concentration of Voriconazole can be increased when it is combined with Ethinylestradiol.]
[S01FA01, atropine, Ethinylestradiol may decrease the excretion rate of Atropine which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Ethinylestradiol.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Ethinylestradiol.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Ethinylestradiol.]
[H02AB11, prednylidene, The serum concentration of Prednylidene can be increased when it is combined with Ethinylestradiol.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Ethinylestradiol.]
[J01CA09, azlocillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Azlocillin.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Ethinylestradiol.]
[L01FX02, gemtuzumab ozogamicin, Ethinylestradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin.]
[L01FD02, pertuzumab, Ethinylestradiol may increase the thrombogenic activities of Pertuzumab.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Ethinylestradiol.]
[V03AX03, cobicistat, The serum concentration of Ethinylestradiol can be decreased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Ethinylestradiol can be decreased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Ethinylestradiol can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Ethinylestradiol can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The serum concentration of Ethinylestradiol can be decreased when it is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Defibrotide.]
[H02AA01, aldosterone, The serum concentration of Aldosterone can be increased when it is combined with Ethinylestradiol.]
[L01EX05, regorafenib, The metabolism of Ethinylestradiol can be decreased when combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Ethinylestradiol can be increased when combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Ethinylestradiol can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Ethinylestradiol.]
[N04BD02, rasagiline, The metabolism of Rasagiline can be decreased when combined with Ethinylestradiol.]
[C08CA13, lercanidipine, The metabolism of Ethinylestradiol can be decreased when combined with Lercanidipine.]
[N06DA02, donepezil, The metabolism of Ethinylestradiol can be decreased when combined with Donepezil.]
[N03AX22, perampanel, The metabolism of Ethinylestradiol can be increased when combined with Perampanel.]
[N02CC03, zolmitriptan, The metabolism of Ethinylestradiol can be decreased when combined with Zolmitriptan.]
[L01EX07, cabozantinib, The metabolism of Ethinylestradiol can be decreased when combined with Cabozantinib.]
[G04BE03, sildenafil, The metabolism of Ethinylestradiol can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Ethinylestradiol.]
[B01AF02, apixaban, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Apixaban.]
[J06BC02, raxibacumab, Ethinylestradiol may increase the thrombogenic activities of Raxibacumab.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethinylestradiol.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Ethinylestradiol can be increased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Ethinylestradiol.]
[G03XC05, ospemifene, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Ospemifene.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethinylestradiol.]
[J01MA15, gemifloxacin, The metabolism of Ethinylestradiol can be decreased when combined with Gemifloxacin.]
[M04AB03, benzbromarone, Ethinylestradiol may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[S01AE07, moxifloxacin, The metabolism of Ethinylestradiol can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Ethinylestradiol can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Ethinylestradiol.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Ethinylestradiol.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Ethinylestradiol.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Ethinylestradiol.]
[M01AH01, celecoxib, The risk or severity of liver damage can be increased when Celecoxib is combined with Ethinylestradiol.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EC02, dabrafenib, The serum concentration of Ethinylestradiol can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Ethinylestradiol can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Ethinylestradiol.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Ethinylestradiol.]
[J05AJ03, dolutegravir, The metabolism of Dolutegravir can be increased when combined with Ethinylestradiol.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Ethinylestradiol.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Ethinylestradiol.]
[A05AA03, cholic acid, Ethinylestradiol may decrease the excretion rate of Cholic Acid which could result in a higher serum level.]
[G03XC02, bazedoxifene, The metabolism of Bazedoxifene can be increased when combined with Ethinylestradiol.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Ethinylestradiol.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Ethinylestradiol.]
[N03AF04, eslicarbazepine, The metabolism of Ethinylestradiol can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Ethinylestradiol can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The metabolism of Ethinylestradiol can be increased when combined with Vigabatrin.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ethinylestradiol.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Ethinylestradiol.]
[A16AA07, metreleptin, The metabolism of Ethinylestradiol can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Ethinylestradiol can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Ethinylestradiol can be increased when combined with Formestane.]
[S03BA03, betamethasone, The serum concentration of Betamethasone can be increased when it is combined with Ethinylestradiol.]
[S01ED02, betaxolol, The metabolism of Ethinylestradiol can be decreased when combined with Betaxolol.]
[B01AE03, argatroban, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Argatroban.]
[C10AB02, bezafibrate, The metabolism of Ethinylestradiol can be decreased when combined with Bezafibrate.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Ethinylestradiol.]
[L04AC11, siltuximab, The metabolism of Ethinylestradiol can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ethinylestradiol can be decreased when combined with Ceritinib.]
[L01FG02, ramucirumab, Ethinylestradiol may increase the thrombogenic activities of Ramucirumab.]
[B01AC26, vorapaxar, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Vorapaxar.]
[L04AA33, vedolizumab, Ethinylestradiol may increase the thrombogenic activities of Vedolizumab.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Acenocoumarol.]
[L01XH04, belinostat, The metabolism of Belinostat can be increased when combined with Ethinylestradiol.]
[L01EM01, idelalisib, The metabolism of Ethinylestradiol can be decreased when combined with Idelalisib.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinylestradiol.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Ethinylestradiol.]
[L01FF02, pembrolizumab, Ethinylestradiol may increase the thrombogenic activities of Pembrolizumab.]
[J01XA05, oritavancin, The metabolism of Ethinylestradiol can be increased when combined with Oritavancin.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ethinylestradiol.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Ethinylestradiol.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Ethinylestradiol.]
[L01FX07, blinatumomab, Ethinylestradiol may increase the thrombogenic activities of Blinatumomab.]
[J05AP09, dasabuvir, The risk or severity of liver enzyme elevations can be increased when Ethinylestradiol is combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Ethinylestradiol.]
[L01FF01, nivolumab, Ethinylestradiol may increase the thrombogenic activities of Nivolumab.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Edoxaban.]
[N06AX11, mirtazapine, The metabolism of Ethinylestradiol can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Ethinylestradiol can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Lenvatinib.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Ethinylestradiol.]
[N02BE01, acetaminophen, The serum concentration of Acetaminophen can be decreased when it is combined with Ethinylestradiol.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Tioclomarol.]
[J05AP06, asunaprevir, The serum concentration of Ethinylestradiol can be decreased when it is combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Cangrelor.]
[C10AX14, alirocumab, Ethinylestradiol may increase the thrombogenic activities of Alirocumab.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Flibanserin.]
[C10AX13, evolocumab, Ethinylestradiol may increase the thrombogenic activities of Evolocumab.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Ethinylestradiol.]
[M02AA25, aceclofenac, Aceclofenac may increase the thrombogenic activities of Ethinylestradiol.]
[S01EC01, acetazolamide, The metabolism of Ethinylestradiol can be increased when combined with Acetazolamide.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Ethinylestradiol.]
[D05BB02, acitretin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Acitretin.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Ethinylestradiol.]
[V03AB37, idarucizumab, Ethinylestradiol may increase the thrombogenic activities of Idarucizumab.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Ethinylestradiol.]
[A16AB13, asfotase alfa, Ethinylestradiol may increase the thrombogenic activities of Asfotase alfa.]
[R03DX09, mepolizumab, Ethinylestradiol may increase the thrombogenic activities of Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Ethinylestradiol can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Ethinylestradiol can be decreased when it is combined with Osimertinib.]
[L01FC01, daratumumab, Ethinylestradiol may increase the thrombogenic activities of Daratumumab.]
[L01FE03, necitumumab, Ethinylestradiol may increase the thrombogenic activities of Necitumumab.]
[L01FX08, elotuzumab, Ethinylestradiol may increase the thrombogenic activities of Elotuzumab.]
[J06BB02, tetanus immune globulin, Ethinylestradiol may increase the thrombogenic activities of Tetanus immune globulin, human.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Ethinylestradiol.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ethinylestradiol.]
[M04AB05, lesinurad, The metabolism of Ethinylestradiol can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Ethinylestradiol.]
[N05CA05, aprobarbital, The metabolism of Ethinylestradiol can be increased when combined with Aprobarbital.]
[N03AX23, brivaracetam, The metabolism of Ethinylestradiol can be increased when combined with Brivaracetam.]
[L04AC13, ixekizumab, Ethinylestradiol may increase the thrombogenic activities of Ixekizumab.]
[R03DX08, reslizumab, Ethinylestradiol may increase the thrombogenic activities of Reslizumab.]
[J06BC04, obiltoxaximab, Ethinylestradiol may increase the thrombogenic activities of Obiltoxaximab.]
[L01XX52, venetoclax, The metabolism of Ethinylestradiol can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be decreased when combined with Ethinylestradiol.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Ethinylestradiol.]
[N06AA19, amineptin, The serum concentration of Amineptine can be increased when it is combined with Ethinylestradiol.]
[L01FF05, atezolizumab, Ethinylestradiol may increase the thrombogenic activities of Atezolizumab.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Obeticholic acid.]
[N01BB01, bupivacaine, The metabolism of Levobupivacaine can be decreased when combined with Ethinylestradiol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be increased when combined with Ethinylestradiol.]
[N05BE01, buspirone, The metabolism of Ethinylestradiol can be decreased when combined with Buspirone.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Ethinylestradiol.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Ethinylestradiol.]
[J06BC03, bezlotoxumab, Ethinylestradiol may increase the thrombogenic activities of Bezlotoxumab.]
[L01FX10, olaratumab, Ethinylestradiol may increase the thrombogenic activities of Olaratumab.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Ethinylestradiol.]
[J01CE04, azidocillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Azidocillin.]
[L01XK03, rucaparib, The metabolism of Ethinylestradiol can be decreased when combined with Rucaparib.]
[J01CA06, bacampicillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Bacampicillin.]
[L04AC12, brodalumab, Ethinylestradiol may increase the thrombogenic activities of Brodalumab.]
[L01EF02, ribociclib, The metabolism of Ethinylestradiol can be decreased when combined with Ribociclib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Ethinylestradiol.]
[L01FF04, avelumab, Ethinylestradiol may increase the thrombogenic activities of Avelumab.]
[L04AA36, ocrelizumab, Ethinylestradiol may increase the thrombogenic activities of Ocrelizumab.]
[D11AH05, dupilumab, Ethinylestradiol may increase the thrombogenic activities of Dupilumab.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Ethinylestradiol.]
[N02BF02, pregabalin, The metabolism of Ethinylestradiol can be increased when combined with Pregabalin.]
[N03AX30, beclamide, The metabolism of Ethinylestradiol can be increased when combined with Beclamide.]
[N06BC01, caffeine, The metabolism of Ethinylestradiol can be decreased when combined with Caffeine.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Ethinylestradiol.]
[D05AX03, calcitriol, The metabolism of Ethinylestradiol can be increased when combined with Calcitriol.]
[L04AC01, daclizumab, Ethinylestradiol may increase the thrombogenic activities of Daclizumab.]
[J05AF06, abacavir, The metabolism of Abacavir can be increased when combined with Ethinylestradiol.]
[J05AE09, tipranavir, The metabolism of Ethinylestradiol can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Ethinylestradiol.]
[L04AB02, infliximab, The metabolism of Ethinylestradiol can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Ethinylestradiol can be decreased when combined with Midostaurin.]
[L01FF03, durvalumab, Ethinylestradiol may increase the thrombogenic activities of Durvalumab.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Ethinylestradiol.]
[L04AC14, sarilumab, The metabolism of Ethinylestradiol can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The metabolism of Delafloxacin can be increased when combined with Ethinylestradiol.]
[B01AF04, betrixaban, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Betrixaban.]
[L04AC16, guselkumab, Ethinylestradiol may increase the thrombogenic activities of Guselkumab.]
[L01BC06, capecitabine, The metabolism of Ethinylestradiol can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Ethinylestradiol.]
[J06BD01, palivizumab, Ethinylestradiol may increase the thrombogenic activities of Palivizumab.]
[L01FB01, inotuzumab ozogamicin, Ethinylestradiol may increase the thrombogenic activities of Inotuzumab ozogamicin.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Ethinylestradiol.]
[J05AG03, efavirenz, The metabolism of Ethinylestradiol can be decreased when combined with Efavirenz.]
[L04AC02, basiliximab, Ethinylestradiol may increase the thrombogenic activities of Basiliximab.]
[R03BA02, budesonide, The serum concentration of Budesonide can be increased when it is combined with Ethinylestradiol.]
[L01EL02, acalabrutinib, The metabolism of Ethinylestradiol can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Letermovir can be increased when combined with Ethinylestradiol.]
[R03DX10, benralizumab, Ethinylestradiol may increase the thrombogenic activities of Benralizumab.]
[N06AA15, butriptyline, The serum concentration of Butriptyline can be increased when it is combined with Ethinylestradiol.]
[B02BX06, emicizumab, Ethinylestradiol may increase the thrombogenic activities of Emicizumab.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Ethinylestradiol.]
[N01BX04, capsaicin, The metabolism of Ethinylestradiol can be increased when combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Ethinylestradiol.]
[L02BB05, apalutamide, The metabolism of Ethinylestradiol can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Ethinylestradiol can be decreased when it is combined with Carbamazepine.]
[J01CA03, carbenicillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Carbenicillin.]
[L03AB06, interferon alfa-n1, The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be increased when combined with Ethinylestradiol.]
[J05AX23, ibalizumab, Ethinylestradiol may increase the thrombogenic activities of Ibalizumab.]
[M05BX05, burosumab, Ethinylestradiol may increase the thrombogenic activities of Burosumab.]
[B02BX09, fostamatinib, The metabolism of Ethinylestradiol can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Ethinylestradiol can be increased when combined with Cannabidiol.]
[N02CD01, erenumab, Ethinylestradiol may increase the thrombogenic activities of Erenumab.]
[B02BX08, avatrombopag, The metabolism of Ethinylestradiol can be increased when combined with Avatrombopag.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be increased when combined with Ethinylestradiol.]
[H01CC03, elagolix, The metabolism of Elagolix can be increased when combined with Ethinylestradiol.]
[L01XX62, ivosidenib, The metabolism of Ethinylestradiol can be increased when combined with Ivosidenib.]
[L04AC17, tildrakizumab, Ethinylestradiol may increase the thrombogenic activities of Tildrakizumab.]
[L01FX09, mogamulizumab, Ethinylestradiol may increase the thrombogenic activities of Mogamulizumab.]
[A16AX14, migalastat, The metabolism of Migalastat can be increased when combined with Ethinylestradiol.]
[N03AX17, stiripentol, The metabolism of Ethinylestradiol can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Ethinylestradiol can be increased when combined with Tecovirimat.]
[B06AC05, lanadelumab, Ethinylestradiol may increase the thrombogenic activities of Lanadelumab.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Ethinylestradiol.]
[J01AA13, eravacycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Eravacycline.]
[N02CD03, fremanezumab, Ethinylestradiol may increase the thrombogenic activities of Fremanezumab.]
[L01FF06, cemiplimab, Ethinylestradiol may increase the thrombogenic activities of Cemiplimab.]
[N02CD02, galcanezumab, Ethinylestradiol may increase the thrombogenic activities of Galcanezumab.]
[L01EB07, dacomitinib, The metabolism of Ethinylestradiol can be decreased when combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Omadacycline.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Ethinylestradiol.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Ethinylestradiol.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Ethinylestradiol.]
[M03BA02, carisoprodol, The metabolism of Carisoprodol can be decreased when combined with Ethinylestradiol.]
[L01ED05, lorlatinib, The metabolism of Ethinylestradiol can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Ethinylestradiol can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Ethinylestradiol can be decreased when combined with Carmustine.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Ethinylestradiol.]
[L04AA43, ravulizumab, Ethinylestradiol may increase the thrombogenic activities of Ravulizumab.]
[A06AX05, prucalopride, The serum concentration of Ethinylestradiol can be decreased when it is combined with Prucalopride.]
[B01AX07, caplacizumab, Ethinylestradiol may increase the thrombogenic activities of Caplacizumab.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Ethinylestradiol.]
[P02BX04, triclabendazole, The metabolism of Ethinylestradiol can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Ethinylestradiol can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Ethinylestradiol.]
[J01FA09, clarithromycin, The metabolism of Ethinylestradiol can be decreased when combined with Clarithromycin.]
[N06AX29, brexanolone, The metabolism of Ethinylestradiol can be increased when combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Ethinylestradiol.]
[M05BX06, romosozumab, Ethinylestradiol may increase the thrombogenic activities of Romosozumab.]
[N05BA09, clobazam, The serum concentration of Ethinylestradiol can be decreased when it is combined with Clobazam.]
[J01AA11, clomocycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Clomocycline.]
[H02AB14, cloprednol, The serum concentration of Cloprednol can be increased when it is combined with Ethinylestradiol.]
[C09CA06, candesartan, The metabolism of Ethinylestradiol can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Ethinylestradiol can be increased when combined with Etanercept.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The serum concentration of Cortivazol can be increased when it is combined with Ethinylestradiol.]
[L04AC18, risankizumab, Ethinylestradiol may increase the thrombogenic activities of Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Ethinylestradiol can be decreased when it is combined with Alpelisib.]
[L01FX14, polatuzumab vedotin, Ethinylestradiol may increase the thrombogenic activities of Polatuzumab vedotin.]
[J01DC04, cefaclor, Ethinylestradiol may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[L02BB06, darolutamide, The metabolism of Darolutamide can be increased when combined with Ethinylestradiol.]
[J01CF03, methicillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Meticillin.]
[L01EX15, pexidartinib, The metabolism of Ethinylestradiol can be decreased when combined with Pexidartinib.]
[M03BX08, cyclobenzaprine, The metabolism of Ethinylestradiol can be decreased when combined with Cyclobenzaprine.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Ethinylestradiol.]
[N07XX11, pitolisant, The serum concentration of Ethinylestradiol can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Ethinylestradiol.]
[S01LA06, brolucizumab, Ethinylestradiol may increase the thrombogenic activities of Brolucizumab.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ethinylestradiol.]
[J01DB09, cephradine, The metabolism of Ethinylestradiol can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be increased when it is combined with Ethinylestradiol.]
[L01FD01, trastuzumab, Ethinylestradiol may increase the thrombogenic activities of Trastuzumab.]
[L01FD04, trastuzumab deruxtecan, Ethinylestradiol may increase the thrombogenic activities of Trastuzumab deruxtecan.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Ethinylestradiol.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Ethinylestradiol.]
[N03AX25, cenobamate, The serum concentration of Ethinylestradiol can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Ethinylestradiol can be increased when it is combined with Givosiran.]
[L01EX18, avapritinib, The metabolism of Ethinylestradiol can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, The metabolism of Lemborexant can be decreased when combined with Ethinylestradiol.]
[N05AD10, lumateperone, The metabolism of Lumateperone can be increased when combined with Ethinylestradiol.]
[M01AX21, diacetylrhein, The metabolism of Ethinylestradiol can be decreased when combined with Diacerein.]
[L01FC02, isatuximab, Ethinylestradiol may increase the thrombogenic activities of Isatuximab.]
[N02CD05, eptinezumab, Ethinylestradiol may increase the thrombogenic activities of Eptinezumab.]
[S01AE06, gatifloxacin, The metabolism of Ethinylestradiol can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Ethinylestradiol can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Ethinylestradiol can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The metabolism of Frovatriptan can be decreased when combined with Ethinylestradiol.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Ethinylestradiol.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Ethinylestradiol.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be increased when combined with Ethinylestradiol.]
[N02CC06, eletriptan, The metabolism of Ethinylestradiol can be decreased when combined with Eletriptan.]
[M01AH02, rofecoxib, The metabolism of Ethinylestradiol can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Ethinylestradiol can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Ethinylestradiol.]
[N03AG02, dipropylacetamide, The metabolism of Ethinylestradiol can be increased when combined with Valpromide.]
[S03AA08, chloramphenicol, The metabolism of Ethinylestradiol can be decreased when combined with Chloramphenicol.]
[L01FX17, sacituzumab govitecan, The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Ethinylestradiol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Ethinylestradiol.]
[L01EX17, capmatinib, The metabolism of Ethinylestradiol can be decreased when combined with Capmatinib.]
[N04BX04, opicapone, The metabolism of Ethinylestradiol can be decreased when combined with Opicapone.]
[D07XB03, fluprednidene, The serum concentration of Fluprednidene can be increased when it is combined with Ethinylestradiol.]
[L01EX22, selpercatinib, The serum concentration of Ethinylestradiol can be increased when it is combined with Selpercatinib.]
[B01AE02, lepirudin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Lepirudin.]
[N05CM02, chlormethiazole, The metabolism of Ethinylestradiol can be increased when combined with Clomethiazole.]
[L04AA47, inebilizumab, Ethinylestradiol may increase the thrombogenic activities of Inebilizumab.]
[C08CA17, levamlodipine, The metabolism of Levamlodipine can be decreased when combined with Ethinylestradiol.]
[J05AX29, fostemsavir, The serum concentration of Ethinylestradiol can be increased when it is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Ethinylestradiol.]
[L01FX12, tafasitamab, Ethinylestradiol may increase the thrombogenic activities of Tafasitamab.]
[L01FX15, belantamab mafodotin, Ethinylestradiol may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Ethinylestradiol can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Ethinylestradiol.]
[L01EX23, pralsetinib, The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Pralsetinib.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Ethinylestradiol.]
[N05AA01, chlorpromazine, The risk or severity of liver damage can be increased when Chlorpromazine is combined with Ethinylestradiol.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ethinylestradiol.]
[M03BB03, chlorzoxazone, The metabolism of Ethinylestradiol can be decreased when combined with Chlorzoxazone.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06BX18, vinpocetine, The metabolism of Ethinylestradiol can be increased when combined with Vinpocetine.]
[M01AB08, etodolac, Etodolac may increase the thrombogenic activities of Ethinylestradiol.]
[M02AA06, etofenamate, The therapeutic efficacy of Etofenamate can be decreased when used in combination with Ethinylestradiol.]
[B06AC06, berotralstat, The metabolism of Ethinylestradiol can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Ethinylestradiol can be decreased when combined with Lonafarnib.]
[J06BD04, ansuvimab, Ethinylestradiol may increase the thrombogenic activities of Ansuvimab.]
[L02BX04, relugolix, The metabolism of Relugolix can be decreased when combined with Ethinylestradiol.]
[L01FD06, margetuximab, Ethinylestradiol may increase the thrombogenic activities of Margetuximab.]
[J05AJ04, cabotegravir, The metabolism of Cabotegravir can be increased when combined with Ethinylestradiol.]
[P03AX07, abametapir, The serum concentration of Ethinylestradiol can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Ethinylestradiol can be decreased when combined with Tepotinib.]
[V03AF12, trilaciclib, The metabolism of Ethinylestradiol can be increased when combined with Trilaciclib.]
[N03AX10, felbamate, The metabolism of Ethinylestradiol can be increased when combined with Felbamate.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Ethinylestradiol.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Ethinylestradiol.]
[J01MB07, flumequine, The metabolism of Ethinylestradiol can be decreased when combined with Flumequine.]
[R03BA03, flunisolide, The serum concentration of Flunisolide can be increased when it is combined with Ethinylestradiol.]
[S01JA01, fluorescein, Ethinylestradiol may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Ethinylestradiol.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethinylestradiol.]
[L04AA50, ponesimod, The metabolism of Ponesimod can be increased when combined with Ethinylestradiol.]
[S01LA08, bevacizumab, Ethinylestradiol may increase the thrombogenic activities of Bevacizumab.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Ethinylestradiol can be increased when it is combined with Peginterferon alfa-2b.]
[L01FF07, dostarlimab, Ethinylestradiol may increase the thrombogenic activities of Dostarlimab.]
[L01FX22, loncastuximab tesirine, Ethinylestradiol may increase the thrombogenic activities of Loncastuximab tesirine.]
[A02BA01, cimetidine, The risk or severity of liver damage can be increased when Cimetidine is combined with Ethinylestradiol.]
[N02BF01, gabapentin, The metabolism of Ethinylestradiol can be increased when combined with Gabapentin.]
[N07CA02, cinnarizine, The metabolism of Ethinylestradiol can be decreased when combined with Cinnarizine.]
[L01FX18, amivantamab, Ethinylestradiol may increase the thrombogenic activities of Amivantamab.]
[J01MB06, cinoxacin, The metabolism of Ethinylestradiol can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Ethinylestradiol can be decreased when it is combined with Sotorasib.]
[J06BD05, sotrovimab, Ethinylestradiol may increase the thrombogenic activities of Sotrovimab.]
[S03AA07, ciprofloxacin, The metabolism of Ethinylestradiol can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, Ethinylestradiol may increase the QTc-prolonging activities of Citalopram.]
[N06DX03, aducanumab, Ethinylestradiol may increase the thrombogenic activities of Aducanumab.]
[H01AC07, somapacitan, The therapeutic efficacy of Somapacitan can be decreased when used in combination with Ethinylestradiol.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Ethinylestradiol.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Ethinylestradiol.]
[L04AA51, anifrolumab, Ethinylestradiol may increase the thrombogenic activities of Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Ethinylestradiol.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Lonapegsomatropin can be decreased when used in combination with Ethinylestradiol.]
[L01EB10, mobocertinib, The serum concentration of Ethinylestradiol can be decreased when it is combined with Mobocertinib.]
[L01FX23, tisotumab vedotin, Ethinylestradiol may increase the thrombogenic activities of Tisotumab vedotin.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethinylestradiol.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Ethinylestradiol.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Ethinylestradiol.]
[N06AX25, St. John's wort extract, The metabolism of Ethinylestradiol can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Ethinylestradiol can be decreased when combined with Asciminib.]
[L02BG06, exemestane, The therapeutic efficacy of Exemestane can be decreased when used in combination with Ethinylestradiol.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Ethinylestradiol can be decreased when combined with Ropeginterferon alfa-2b.]
[R03DX11, tezepelumab, Ethinylestradiol may increase the thrombogenic activities of Tezepelumab.]
[D11AH07, tralokinumab, Ethinylestradiol may increase the thrombogenic activities of Tralokinumab.]
[L04AA55, sutimlimab, Ethinylestradiol may increase the thrombogenic activities of Sutimlimab.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Ethinylestradiol.]
[J04BA01, clofazimine, The metabolism of Ethinylestradiol can be decreased when combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Tenecteplase.]
[C10AB01, clofibrate, The serum concentration of Clofibrate can be decreased when it is combined with Ethinylestradiol.]
[B06AX04, mitapivat, The metabolism of Ethinylestradiol can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The metabolism of Levobupivacaine can be decreased when combined with Ethinylestradiol.]
[L01EJ03, pacritinib, The metabolism of Ethinylestradiol can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Ethinylestradiol.]
[N03AE01, clonazepam, The metabolism of Ethinylestradiol can be increased when combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Ethinylestradiol is combined with Clonidine.]
[C01EB24, mavacamten, The serum concentration of Ethinylestradiol can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, Tirzepatide can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Ethinylestradiol.]
[L04AC22, spesolimab, Ethinylestradiol may increase the thrombogenic activities of Spesolimab.]
[A05BA08, glycyrrhizic acid, Ethinylestradiol may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[L01FX20, tremelimumab, Ethinylestradiol may increase the thrombogenic activities of Tremelimumab.]
[H01CC04, linzagolix, The serum concentration of Ethinylestradiol can be increased when it is combined with Linzagolix.]
[A04AA01, ondansetron, The metabolism of Ethinylestradiol can be decreased when combined with Ondansetron.]
[J01CF02, cloxacillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Cloxacillin.]
[J05AX31, lenacapavir, The metabolism of Lenacapavir can be increased when combined with Ethinylestradiol.]
[N05AH02, clozapine, The metabolism of Ethinylestradiol can be decreased when combined with Clozapine.]
[L04AA57, ublituximab, Ethinylestradiol may increase the thrombogenic activities of Ublituximab.]
[L01FE02, panitumumab, Ethinylestradiol may increase the thrombogenic activities of Panitumumab.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Ethinylestradiol.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Ethinylestradiol.]
[H01AC08, somatrogon, The metabolism of Ethinylestradiol can be increased when combined with Somatrogon.]
[M09AX11, palovarotene, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Palovarotene.]
[L04AC21, bimekizumab, The metabolism of Ethinylestradiol can be increased when combined with Bimekizumab.]
[J06BB04, hepatitis B immune globulin, Ethinylestradiol may increase the thrombogenic activities of Hepatitis B immune globulin.]
[J01CA18, hetacillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Hetacillin.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA13, leflunomide, The serum concentration of Ethinylestradiol can be decreased when it is combined with Leflunomide.]
[C04AX28, ifenprodil, The metabolism of Ethinylestradiol can be increased when combined with Ifenprodil.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Ethinylestradiol.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Ethinylestradiol.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ethinylestradiol.]
[J01FA15, telithromycin, The metabolism of Ethinylestradiol can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The serum concentration of Ciclesonide can be increased when it is combined with Ethinylestradiol.]
[M01AH03, valdecoxib, Valdecoxib may increase the thrombogenic activities of Ethinylestradiol.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Ethinylestradiol.]
[M01AH04, parecoxib, Parecoxib may increase the thrombogenic activities of Ethinylestradiol.]
[J02AC02, itraconazole, The metabolism of Ethinylestradiol can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Bemiparin.]
[S01AD03, acyclovir, The metabolism of Ethinylestradiol can be decreased when combined with Acyclovir.]
[L02BA03, fulvestrant, The metabolism of Fulvestrant can be increased when combined with Ethinylestradiol.]
[L01EA01, imatinib, Ethinylestradiol may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[J02AC04, posaconazole, The metabolism of Ethinylestradiol can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Ethinylestradiol.]
[N03AX09, lamotrigine, Ethinylestradiol may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA03, cortisone, The serum concentration of Cortisone can be increased when it is combined with Ethinylestradiol.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be decreased when combined with Ethinylestradiol.]
[S01AE04, lomefloxacin, The metabolism of Lomefloxacin can be decreased when combined with Ethinylestradiol.]
[R06AX13, loratadine, Ethinylestradiol may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[C08CA11, manidipine, The metabolism of Ethinylestradiol can be decreased when combined with Manidipine.]
[H02AB15, meprednisone, The serum concentration of Meprednisone can be increased when it is combined with Ethinylestradiol.]
[J01CA14, methampicillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Metampicillin.]
[R06AE03, cyclizine, The metabolism of Ethinylestradiol can be decreased when combined with Cyclizine.]
[C03DA04, eplerenone, The metabolism of Ethinylestradiol can be decreased when combined with Eplerenone.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Ethinylestradiol.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Ethinylestradiol.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Ethinylestradiol.]
[N06AG02, moclobemide, The metabolism of Moclobemide can be decreased when combined with Ethinylestradiol.]
[N06BA07, modafinil, The metabolism of Ethinylestradiol can be increased when combined with Modafinil.]
[C10AA07, rosuvastatin, Rosuvastatin may decrease the excretion rate of Ethinylestradiol which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Ethinylestradiol can be decreased when combined with Conivaptan.]
[R03DX05, omalizumab, Ethinylestradiol may increase the thrombogenic activities of Omalizumab.]
[J05AF10, entecavir, The metabolism of Ethinylestradiol can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The metabolism of Ethinylestradiol can be decreased when combined with Vardenafil.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Ethinylestradiol.]
[L01AX04, dacarbazine, The metabolism of Ethinylestradiol can be decreased when combined with Dacarbazine.]
[G03XA01, danazol, The metabolism of Ethinylestradiol can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The therapeutic efficacy of Dantrolene can be decreased when used in combination with Ethinylestradiol.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Ethinylestradiol.]
[L01DB02, daunorubicin, Ethinylestradiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[G03XX01, prasterone, The risk or severity of adverse effects can be increased when Prasterone is combined with Ethinylestradiol.]
[A04AD11, nabilone, The metabolism of Ethinylestradiol can be decreased when combined with Nabilone.]
[M01AX01, nabumetone, The metabolism of Ethinylestradiol can be decreased when combined with Nabumetone.]
[J01AA01, demeclocycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Demeclocycline.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Ethinylestradiol.]
[N06AX06, nefazodone, The metabolism of Ethinylestradiol can be decreased when combined with Nefazodone.]
[L02BB02, nilutamide, The metabolism of Ethinylestradiol can be decreased when combined with Nilutamide.]
[L01FE01, cetuximab, Ethinylestradiol may increase the thrombogenic activities of Cetuximab.]
[N03AG06, tiagabine, The metabolism of Ethinylestradiol can be increased when combined with Tiagabine.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Ethinylestradiol.]
[B01AX05, fondaparinux, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Fondaparinux.]
[N06AB10, escitalopram, The metabolism of Escitalopram can be decreased when combined with Ethinylestradiol.]
[N06AA01, desipramine, The serum concentration of Desipramine can be increased when it is combined with Ethinylestradiol.]
[D07XC02, desoximetasone, The serum concentration of Desoximetasone can be increased when it is combined with Ethinylestradiol.]
[H02AA03, desoxycorticosterone, The serum concentration of Desoxycortone can be increased when it is combined with Ethinylestradiol.]
[N03AF02, oxcarbazepine, The serum concentration of Ethinylestradiol can be decreased when it is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The serum concentration of Dexamethasone can be increased when it is combined with Ethinylestradiol.]
[G04BD04, oxybutynin, The metabolism of Ethinylestradiol can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Ethinylestradiol.]
[L04AB04, adalimumab, The metabolism of Ethinylestradiol can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Ethinylestradiol can be decreased when combined with Gefitinib.]
[R05DA09, dextromethorphan, The metabolism of Ethinylestradiol can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The metabolism of Ethinylestradiol can be increased when combined with Paramethadione.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be decreased when combined with Ethinylestradiol.]
[B01AC04, clopidogrel, The metabolism of Ethinylestradiol can be decreased when combined with Clopidogrel.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Ethinylestradiol.]
[N05BA01, diazepam, The metabolism of Ethinylestradiol can be increased when combined with Diazepam.]
[N03AX07, phenacemide, The metabolism of Ethinylestradiol can be increased when combined with Phenacemide.]
[J01CE05, phenethicillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Pheneticillin.]
[N03AD02, phensuximide, The metabolism of Ethinylestradiol can be increased when combined with Phensuximide.]
[N06AA08, dibenzepin, The serum concentration of Dibenzepin can be increased when it is combined with Ethinylestradiol.]
[S01BC03, diclofenac, Ethinylestradiol may decrease the excretion rate of Diclofenac which could result in a higher serum level.]
[J01CF01, dicloxacillin, The metabolism of Ethinylestradiol can be increased when combined with Dicloxacillin.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ethinylestradiol.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Ethinylestradiol.]
[L02AA01, diethylstilbestrol, Ethinylestradiol may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.]
[C08CA03, isradipine, Ethinylestradiol may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[D07XC04, diflucortolone, The serum concentration of Difluocortolone can be increased when it is combined with Ethinylestradiol.]
[N02BA11, diflunisal, The metabolism of Ethinylestradiol can be decreased when combined with Diflunisal.]
[C01AA05, digoxin, Ethinylestradiol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, The metabolism of Ethinylestradiol can be decreased when combined with Dihydralazine.]
[C10AX09, ezetimibe, Ethinylestradiol may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Ethinylestradiol may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02AA03, hydromorphone, The metabolism of Ethinylestradiol can be decreased when combined with Hydromorphone.]
[L04AX04, lenalidomide, Ethinylestradiol may increase the thrombogenic activities of Lenalidomide.]
[J05AE08, atazanavir, The metabolism of Ethinylestradiol can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Ethinylestradiol.]
[C08DB01, diltiazem, The metabolism of Ethinylestradiol can be decreased when combined with Diltiazem.]
[N03AG05, progabide, The metabolism of Ethinylestradiol can be increased when combined with Progabide.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Ethinylestradiol.]
[J01CE03, propicillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Propicillin.]
[C05CA03, diosmin, The metabolism of Ethinylestradiol can be decreased when combined with Diosmin.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Ethinylestradiol.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Ethinylestradiol.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Ethinylestradiol.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Dipyridamole.]
[B01AD10, drotrecogin alfa, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, The serum concentration of Quinupramine can be increased when it is combined with Ethinylestradiol.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Ethinylestradiol.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Ethinylestradiol.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Ethinylestradiol.]
[J06BB01, Rho(D) immune globulin, Ethinylestradiol may increase the thrombogenic activities of Human Rho(D) immune globulin.]
[L04AA23, natalizumab, Ethinylestradiol may increase the thrombogenic activities of Natalizumab.]
[P03AA04, disulfiram, Ethinylestradiol may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[S02AA12, rifamycin SV, The metabolism of Ethinylestradiol can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Ethinylestradiol can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The metabolism of Ethinylestradiol can be increased when combined with Riluzole.]
[N05AX08, risperidone, The metabolism of Ethinylestradiol can be decreased when combined with Risperidone.]
[L04AA21, efalizumab, Ethinylestradiol may increase the thrombogenic activities of Efalizumab.]
[N01BB09, ropivacaine, The metabolism of Ethinylestradiol can be decreased when combined with Ropivacaine.]
[J01MB01, rosoxacin, The metabolism of Ethinylestradiol can be decreased when combined with Rosoxacin.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Ethinylestradiol.]
[A04AD12, aprepitant, The serum concentration of Ethinylestradiol can be decreased when it is combined with Aprepitant.]
[L01XG01, bortezomib, The metabolism of Ethinylestradiol can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, The metabolism of Ethinylestradiol can be decreased when combined with Tadalafil.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Ethinylestradiol.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Ethinylestradiol.]
[C01EB18, ranolazine, Ethinylestradiol may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[R03AC12, salmeterol, The metabolism of Ethinylestradiol can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Ethinylestradiol.]
[N06AA16, dothiepin, The metabolism of Ethinylestradiol can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Ethinylestradiol.]
[L01DB01, doxorubicin, Ethinylestradiol may decrease the excretion rate of Doxorubicin which could result in a higher serum level.]
[J01AA02, doxycycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Doxycycline.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Ethinylestradiol.]
[C10AA01, simvastatin, Ethinylestradiol may decrease the excretion rate of Simvastatin which could result in a higher serum level.]
[H01AA01, corticotropin, The serum concentration of Corticotropin can be increased when it is combined with Ethinylestradiol.]
[J01MA05, temafloxacin, The metabolism of Ethinylestradiol can be decreased when combined with Temafloxacin.]
[J01CA17, temocillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Temocillin.]
[M01AC02, tenoxicam, The metabolism of Ethinylestradiol can be decreased when combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Ethinylestradiol can be increased when combined with Terbinafine.]
[N06AX14, tianeptine, The serum concentration of Tianeptine can be increased when it is combined with Ethinylestradiol.]
[N03AX11, topiramate, The metabolism of Ethinylestradiol can be increased when combined with Topiramate.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Ethinylestradiol.]
[J01AA12, tigecycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Tigecycline.]
[B01AC18, triflusal, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Triflusal.]
[H02CA01, trilostane, The serum concentration of Trilostane can be increased when it is combined with Ethinylestradiol.]
[C05CA04, troxerutin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Troxerutin.]
[J01MA04, enoxacin, The metabolism of Ethinylestradiol can be decreased when combined with Enoxacin.]
[J06BB03, varicella-zoster immune globulin, Ethinylestradiol may increase the thrombogenic activities of Human varicella-zoster immune globulin.]
[C08CA12, mepirodipine, The metabolism of Ethinylestradiol can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Ethinylestradiol can be decreased when combined with Epinephrine.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Ethinylestradiol.]
[N03AX15, zonisamide, The metabolism of Ethinylestradiol can be increased when combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Ethinylestradiol.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Ethinylestradiol.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Ethinylestradiol.]
[B01AD03, anistreplase, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Anistreplase.]
[N02CA02, ergotamine, The metabolism of Ethinylestradiol can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The metabolism of Ethinylestradiol can be increased when combined with Valproic acid.]
[S01AA17, erythromycin, Ethinylestradiol may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[N05CD04, estazolam, The metabolism of Ethinylestradiol can be increased when combined with Estazolam.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Ethinylestradiol.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Ethinylestradiol.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Ethinylestradiol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Ethinylestradiol can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Ethinylestradiol can be decreased when combined with Ethambutol.]
[R03BA05, fluticasone, The serum concentration of Fluticasone can be increased when it is combined with Ethinylestradiol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be increased when combined with Ethinylestradiol.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, Ethinylestradiol may increase the thrombogenic activities of Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be increased when combined with Ethinylestradiol.]
[J01MB04, pipemidic acid, The metabolism of Ethinylestradiol can be decreased when combined with Pipemidic acid.]
[S02BA08, fluocinolone acetonide, The serum concentration of Fluocinolone acetonide can be increased when it is combined with Ethinylestradiol.]
[M01AG01, mefenamic acid, The metabolism of Ethinylestradiol can be decreased when combined with Mefenamic acid.]
[R03BA09, fluticasone furoate, The serum concentration of Fluticasone furoate can be increased when it is combined with Ethinylestradiol.]
[N03AD01, ethosuximide, The metabolism of Ethinylestradiol can be increased when combined with Ethosuximide.]
[N03AB01, ethotoin, The metabolism of Ethinylestradiol can be increased when combined with Ethotoin.]
[M01AC06, meloxicam, Meloxicam may increase the thrombogenic activities of Ethinylestradiol.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Ethinylestradiol.]
[D05BB01, etretinate, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Etretinate.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be decreased when combined with Ethinylestradiol.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Ethinylestradiol.]
[R06AX12, terfenadine, The metabolism of Ethinylestradiol can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Bupropion can be decreased when combined with Ethinylestradiol.]
[N06AB08, fluvoxamine, The metabolism of Ethinylestradiol can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Ethinylestradiol.]
[L04AA02, muromonab-CD3, Ethinylestradiol may increase the thrombogenic activities of Muromonab.]
[C10AA03, pravastatin, Ethinylestradiol may decrease the excretion rate of Pravastatin which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, The metabolism of Ethinylestradiol can be decreased when combined with Sodium aurothiomalate.]
[B05AA05, dextran, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Dextran.]
[A02BA03, famotidine, The metabolism of Ethinylestradiol can be decreased when combined with Famotidine.]
[P02CA03, albendazole, The metabolism of Ethinylestradiol can be increased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Ethinylestradiol can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The metabolism of Ethinylestradiol can be increased when combined with Fenfluramine.]
[B01AD05, plasmin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Fibrinolysin.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Ethinylestradiol.]
[J01CF05, floxacillin, Ethinylestradiol may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.]
[J02AC01, fluconazole, The bioavailability of Ethinylestradiol can be increased when combined with Fluconazole.]
[H02AA02, fludrocortisone, The serum concentration of Fludrocortisone can be increased when it is combined with Ethinylestradiol.]
[D07XB01, flumethasone, The serum concentration of Flumethasone can be increased when it is combined with Ethinylestradiol.]
[N07CA03, flunarizine, The metabolism of Ethinylestradiol can be increased when combined with Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Ethinylestradiol can be decreased when combined with Flunitrazepam.]
[D07AC08, fluocinonide, The serum concentration of Fluocinonide can be increased when it is combined with Ethinylestradiol.]
[N06AA14, melitracen, The serum concentration of Melitracen can be increased when it is combined with Ethinylestradiol.]
[H02AB03, fluocortolone, The serum concentration of Fluocortolone can be increased when it is combined with Ethinylestradiol.]
[V03AZ01, ethanol, The metabolism of Ethinylestradiol can be increased when combined with Ethanol.]
[L01BC09, floxuridine, The metabolism of Ethinylestradiol can be decreased when combined with Floxuridine.]
[S01CB05, fluorometholone, The serum concentration of Fluorometholone can be increased when it is combined with Ethinylestradiol.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Ethinylestradiol.]
[N06AB03, fluoxetine, The metabolism of Ethinylestradiol can be decreased when combined with Fluoxetine.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be increased when combined with Ethinylestradiol.]
[L02BB01, flutamide, The metabolism of Ethinylestradiol can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Ethinylestradiol.]
[J05AE10, darunavir, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Ethinylestradiol.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Ethinylestradiol.]
[N03AA04, barbexaclone, The metabolism of Ethinylestradiol can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, The metabolism of Ethinylestradiol can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Ethinylestradiol.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Ethinylestradiol.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Ethinylestradiol.]
[J05AG04, etravirine, The metabolism of Ethinylestradiol can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The metabolism of Ethinylestradiol can be increased when combined with Methsuximide.]
[N01AH02, alfentanil, The metabolism of Ethinylestradiol can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Ethinylestradiol.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Ethinylestradiol.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Ethinylestradiol.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Ethinylestradiol.]
[N05CM18, dexmedetomidine, The metabolism of Ethinylestradiol can be decreased when combined with Dexmedetomidine.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Ethinylestradiol.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ethinylestradiol.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Ethinylestradiol.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Fluindione.]
[D01BA01, griseofulvin, The metabolism of Ethinylestradiol can be increased when combined with Griseofulvin.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Ethinylestradiol.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Ethinylestradiol.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Ethinylestradiol.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be decreased when combined with Ethinylestradiol.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Ethinylestradiol.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Ethinylestradiol.]
[C09CA01, losartan, Ethinylestradiol may decrease the excretion rate of Losartan which could result in a higher serum level.]
[S01XA14, heparin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Heparin.]
[N05CA16, hexobarbital, The metabolism of Ethinylestradiol can be increased when combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Ethinylestradiol can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Ethinylestradiol can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the thrombogenic activities of Ethinylestradiol.]
[S02BA01, hydrocortisone, The serum concentration of Hydrocortisone can be increased when it is combined with Ethinylestradiol.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Ethinylestradiol.]
[N05BB01, hydroxyzine, The metabolism of Ethinylestradiol can be decreased when combined with Hydroxyzine.]
[J04AB04, rifabutin, Rifabutin may increase the excretion rate of Ethinylestradiol which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be increased when combined with Ethinylestradiol.]
[B05CB02, sodium citrate, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Ethinylestradiol.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Ethinylestradiol.]
[H01AC02, somatrem, The metabolism of Ethinylestradiol can be increased when combined with Somatrem.]
[N06AA02, imipramine, The metabolism of Imipramine can be decreased when combined with Ethinylestradiol.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Ethinylestradiol.]
[R01AD07, tixocortol, The serum concentration of Tixocortol can be increased when it is combined with Ethinylestradiol.]
[M03BX02, tizanidine, The metabolism of Ethinylestradiol can be increased when combined with Tizanidine.]
[S01BC01, indomethacin, Ethinylestradiol may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The metabolism of Ethinylestradiol can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, Ethinylestradiol may increase the thrombogenic activities of Eculizumab.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ethinylestradiol.]
[S01LA04, ranibizumab, Ethinylestradiol may increase the thrombogenic activities of Ranibizumab.]
[N05BA12, alprazolam, The metabolism of Ethinylestradiol can be decreased when combined with Alprazolam.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Ethinylestradiol.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ethinylestradiol.]
[C10AA06, cerivastatin, Ethinylestradiol may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[L01XX35, anagrelide, The metabolism of Ethinylestradiol can be decreased when combined with Anagrelide.]
[L03AB09, interferon alfacon-1, The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfacon-1.]
[N06AA13, iprindole, The serum concentration of Iprindole can be increased when it is combined with Ethinylestradiol.]
[N06AF05, iproniazid, The metabolism of Ethinylestradiol can be decreased when combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Ethinylestradiol can be decreased when combined with Penciclovir.]
[P01AX06, atovaquone, The metabolism of Ethinylestradiol can be decreased when combined with Atovaquone.]
[N04BX02, entacapone, The metabolism of Ethinylestradiol can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Ethinylestradiol can be decreased when combined with Isoniazid.]
[A10BJ01, exenatide, Exenatide can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[D10BA01, isotretinoin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Isotretinoin.]
[B01AE06, bivalirudin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Bivalirudin.]
[H01AC01, somatropin, The therapeutic efficacy of Somatotropin can be decreased when used in combination with Ethinylestradiol.]
[L04AC07, tocilizumab, The metabolism of Ethinylestradiol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Ethinylestradiol.]
[B01AC22, prasugrel, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Ethinylestradiol can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The metabolism of Ethinylestradiol can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, The metabolism of Ketoprofen can be increased when combined with Ethinylestradiol.]
[V03AC03, deferasirox, The metabolism of Deferasirox can be increased when combined with Ethinylestradiol.]
[L04AA24, abatacept, The metabolism of Ethinylestradiol can be increased when combined with Abatacept.]
[J01MB02, nalidixic acid, The metabolism of Ethinylestradiol can be decreased when combined with Nalidixic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be increased when combined with Ethinylestradiol.]
[N03AX18, lacosamide, The metabolism of Ethinylestradiol can be increased when combined with Lacosamide.]
[J01CA11, amdinocillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Amdinocillin.]
[J01CA08, amdinocillin pivoxil, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Pivmecillinam.]
[S02DA01, lidocaine, The metabolism of Ethinylestradiol can be decreased when combined with Lidocaine.]
[N06BA13, armodafinil, The metabolism of Ethinylestradiol can be increased when combined with Armodafinil.]
[N06AA07, lofepramine, The serum concentration of Lofepramine can be increased when it is combined with Ethinylestradiol.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Ethinylestradiol.]
[N05BA06, lorazepam, The metabolism of Ethinylestradiol can be increased when combined with Lorazepam.]
[C10AA02, lovastatin, Ethinylestradiol may decrease the excretion rate of Lovastatin which could result in a higher serum level.]
[J01AA04, lymecycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Lymecycline.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Ethinylestradiol.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Ethinylestradiol.]
[V04CC02, magnesium sulfate, The metabolism of Ethinylestradiol can be increased when combined with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Ethinylestradiol can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The metabolism of Ethinylestradiol can be decreased when combined with Maprotiline.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Meclofenamic acid can be decreased when used in combination with Ethinylestradiol.]
[N05BA03, medazepam, The metabolism of Ethinylestradiol can be increased when combined with Medazepam.]
[B01AB06, nadroparin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Dalteparin.]
[N05CH01, melatonin, The metabolism of Melatonin can be decreased when combined with Ethinylestradiol.]
[N03AB04, mephenytoin, The metabolism of Ethinylestradiol can be increased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Ethinylestradiol can be increased when combined with Methylphenobarbital.]
[L02BG01, aminoglutethimide, The metabolism of Ethinylestradiol can be increased when combined with Aminoglutethimide.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be decreased when combined with Ethinylestradiol.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Ethinylestradiol.]
[J01AA05, methacycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Metacycline.]
[N07BC02, methadone, The metabolism of Methadone can be decreased when combined with Ethinylestradiol.]
[N03AA30, metharbital, The metabolism of Ethinylestradiol can be increased when combined with Metharbital.]
[H03BB02, methimazole, The metabolism of Ethinylestradiol can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Ethinylestradiol can be decreased when combined with Pemetrexed.]
[N05CA15, methohexital, The metabolism of Ethinylestradiol can be increased when combined with Methohexital.]
[D05BA02, methoxsalen, The metabolism of Ethinylestradiol can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Ethinylestradiol.]
[V04CG05, methylene blue, The metabolism of Ethinylestradiol can be decreased when combined with Methylene blue.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Ethinylestradiol.]
[H02AB04, methylprednisolone, The serum concentration of Methylprednisolone can be increased when it is combined with Ethinylestradiol.]
[D07AC14, methylprednisolone aceponate, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Ethinylestradiol.]
[N03AF03, rufinamide, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Rufinamide.]
[A03FA01, metoclopramide, The metabolism of Metoclopramide can be decreased when combined with Ethinylestradiol.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be increased when combined with Ethinylestradiol.]
[V04CD01, metyrapone, The metabolism of Ethinylestradiol can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Ethinylestradiol can be decreased when combined with Mexiletine.]
[J01CA10, mezlocillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Mezlocillin.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Ethinylestradiol.]
[S02AA13, miconazole, The metabolism of Ethinylestradiol can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Ethinylestradiol.]
[B01AB07, parnaparin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Parnaparin.]
[N05CD08, midazolam, The metabolism of Ethinylestradiol can be decreased when combined with Midazolam.]
[G03XB01, mifepristone, The serum concentration of Ethinylestradiol can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Tinzaparin.]
[C09CA03, valsartan, The metabolism of Ethinylestradiol can be decreased when combined with Valsartan.]
[J01AA08, minocycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Minocycline.]
[D11AX01, minoxidil, The metabolism of Minoxidil can be increased when combined with Ethinylestradiol.]
[L01XX23, mitotane, The metabolism of Ethinylestradiol can be increased when combined with Mitotane.]
[C01BD01, amiodarone, The metabolism of Ethinylestradiol can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Ethinylestradiol can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, Ethinylestradiol may increase the excretion rate of Morphine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB05, certolizumab pegol, The metabolism of Ethinylestradiol can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be increased when combined with Ethinylestradiol.]
[L04AA52, ofatumumab, Ethinylestradiol may increase the thrombogenic activities of Ofatumumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Ethinylestradiol.]
[L04AA06, mycophenolic acid, The serum concentration of Ethinylestradiol can be decreased when it is combined with Mycophenolic acid.]
[N05CA02, amobarbital, The metabolism of Ethinylestradiol can be increased when combined with Amobarbital.]
[J05AJ01, raltegravir, The metabolism of Raltegravir can be increased when combined with Ethinylestradiol.]
[P01BA06, amodiaquine, The metabolism of Amodiaquine can be decreased when combined with Ethinylestradiol.]
[G03XC01, raloxifene, The metabolism of Raloxifene can be increased when combined with Ethinylestradiol.]
[N06AA17, amoxapine, The serum concentration of Amoxapine can be increased when it is combined with Ethinylestradiol.]
[N03AB05, fosphenytoin, The serum concentration of Ethinylestradiol can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Ethinylestradiol can be decreased when combined with Interferon beta-1b.]
[J01CA04, amoxicillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Amoxicillin.]
[N04BC04, ropinirole, Ethinylestradiol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CF06, nafcillin, The metabolism of Ethinylestradiol can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Ethinylestradiol can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The metabolism of Naltrexone can be increased when combined with Ethinylestradiol.]
[L04AC03, anakinra, The metabolism of Ethinylestradiol can be increased when combined with Anakinra.]
[M02AA12, naproxen, Ethinylestradiol may decrease the excretion rate of Naproxen which could result in a higher serum level.]
[A10BG01, troglitazone, The metabolism of Troglitazone can be increased when combined with Ethinylestradiol.]
[N06AX21, duloxetine, The metabolism of Ethinylestradiol can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, The metabolism of Ethinylestradiol can be decreased when combined with Tolcapone.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Ethinylestradiol.]
[A10BX02, repaglinide, Ethinylestradiol may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Ethinylestradiol.]
[S01AA19, ampicillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Ampicillin.]
[N06AX23, desvenlafaxine, The metabolism of Ethinylestradiol can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Ethinylestradiol may decrease the excretion rate of Telmisartan which could result in a higher serum level.]
[M04AA03, febuxostat, The metabolism of Febuxostat can be increased when combined with Ethinylestradiol.]
[C08CA04, nicardipine, The metabolism of Ethinylestradiol can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Ethinylestradiol can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, Ethinylestradiol may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The metabolism of Ethinylestradiol can be decreased when combined with Niflumic acid.]
[C08CA07, nisoldipine, The metabolism of Ethinylestradiol can be decreased when combined with Nisoldipine.]
[N05CD02, nitrazepam, The metabolism of Ethinylestradiol can be increased when combined with Nitrazepam.]
[C08CA08, nitrendipine, Ethinylestradiol may decrease the excretion rate of Nitrendipine which could result in a higher serum level.]
[J01XE01, nitrofurantoin, The therapeutic efficacy of Nitrofurantoin can be decreased when used in combination with Ethinylestradiol.]
[N05CF03, zaleplon, The metabolism of Ethinylestradiol can be increased when combined with Zaleplon.]
[S01AE02, norfloxacin, The metabolism of Ethinylestradiol can be decreased when combined with Norfloxacin.]
[C02KX01, bosentan, The serum concentration of Ethinylestradiol can be decreased when it is combined with Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Ethinylestradiol.]
[R05DA07, noscapine, The metabolism of Ethinylestradiol can be decreased when combined with Noscapine.]
[L03AB07, interferon beta-1a, The metabolism of Ethinylestradiol can be decreased when combined with Interferon beta-1a.]
[B01AB08, reviparin, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Reviparin.]
[H01CB02, octreotide, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, Ethinylestradiol may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[L04AC04, rilonacept, The metabolism of Ethinylestradiol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Ethinylestradiol can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The serum concentration of Opipramol can be increased when it is combined with Ethinylestradiol.]
[B01AD07, reteplase, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Ancrod.]
[J01CF04, oxacillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Oxacillin.]
[A14AA08, oxandrolone, The metabolism of Ethinylestradiol can be decreased when combined with Oxandrolone.]
[N02AA05, oxycodone, The metabolism of Ethinylestradiol can be decreased when combined with Oxycodone.]
[S01AA04, oxytetracycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Oxytetracycline.]
[N05AH05, asenapine, The metabolism of Asenapine can be decreased when combined with Ethinylestradiol.]
[B01AB09, danaparoid, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Danaparoid.]
[N05CC05, paraldehyde, The metabolism of Ethinylestradiol can be increased when combined with Paraldehyde.]
[H02AB05, paramethasone, The serum concentration of Paramethasone can be increased when it is combined with Ethinylestradiol.]
[J01MA03, pefloxacin, The metabolism of Ethinylestradiol can be decreased when combined with Pefloxacin.]
[S01AA14, penicillin G, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Benzylpenicillin.]
[J01CE09, penicillin G procaine, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Procaine benzylpenicillin.]
[J01CE02, penicillin V, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Phenoxymethylpenicillin.]
[N05CA01, pentobarbital, The metabolism of Ethinylestradiol can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, The metabolism of Ethinylestradiol can be decreased when combined with Pentoxifylline.]
[L01FX01, edrecolomab, Ethinylestradiol may increase the thrombogenic activities of Edrecolomab.]
[N05AB03, perphenazine, The metabolism of Ethinylestradiol can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Ethinylestradiol.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Ethinylestradiol.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Ethinylestradiol can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Phenprocoumon.]
[M02AA01, phenylbutazone, The metabolism of Ethinylestradiol can be increased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The metabolism of Ethinylestradiol can be increased when combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Ethinylestradiol.]
[N03AB02, phenytoin, The serum concentration of Ethinylestradiol can be decreased when it is combined with Phenytoin.]
[L01XF02, alitretinoin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Alitretinoin.]
[L04AB06, golimumab, The metabolism of Ethinylestradiol can be increased when combined with Golimumab.]
[C08CX01, mibefradil, The metabolism of Ethinylestradiol can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Ethinylestradiol.]
[C10AA05, atorvastatin, Ethinylestradiol may decrease the excretion rate of Atorvastatin which could result in a higher serum level.]
[J01CA12, piperacillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Piperacillin.]
[J05AE01, saquinavir, The metabolism of Ethinylestradiol can be decreased when combined with Saquinavir.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Ethinylestradiol.]
[J01MA11, grepafloxacin, The metabolism of Ethinylestradiol can be decreased when combined with Grepafloxacin.]
[J01CA02, pivampicillin, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Pivampicillin.]
[J05AG02, delavirdine, The metabolism of Ethinylestradiol can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Ethinylestradiol can be decreased when combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Abciximab.]
[D05AX05, tazarotene, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Tazarotene.]
[S01XA13, alteplase, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Alteplase.]
[A10BG02, rosiglitazone, Ethinylestradiol may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[L04AC05, ustekinumab, Ethinylestradiol may increase the thrombogenic activities of Ustekinumab.]
[L02BG03, anastrozole, The therapeutic efficacy of Anastrozole can be decreased when used in combination with Ethinylestradiol.]
[A03AE01, alosetron, The metabolism of Ethinylestradiol can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Ethinylestradiol can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Ethinylestradiol can be decreased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Ethinylestradiol.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ethinylestradiol.]
[C10AA08, pitavastatin, Ethinylestradiol may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Ethinylestradiol.]
[S03BA02, prednisolone, The serum concentration of Prednisolone can be increased when it is combined with Ethinylestradiol.]
[H02AB07, prednisone, The serum concentration of Prednisone can be increased when it is combined with Ethinylestradiol.]
[P01BA03, primaquine, The metabolism of Ethinylestradiol can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Ethinylestradiol can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Ethinylestradiol can be increased when combined with Probenecid.]
[C10AB05, fenofibrate, Ethinylestradiol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, The risk or severity of liver damage can be increased when Progesterone is combined with Ethinylestradiol.]
[N05AA03, promazine, The metabolism of Ethinylestradiol can be decreased when combined with Promazine.]
[R06AD02, promethazine, The metabolism of Ethinylestradiol can be decreased when combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Ethinylestradiol can be decreased when combined with Propafenone.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Ethinylestradiol.]
[N01AX10, propofol, The metabolism of Propofol can be increased when combined with Ethinylestradiol.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Ethinylestradiol.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Ethinylestradiol.]
[N06AA11, protriptyline, The serum concentration of Protriptyline can be increased when it is combined with Ethinylestradiol.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Ethinylestradiol.]
[P01BD01, pyrimethamine, The metabolism of Ethinylestradiol can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Ethinylestradiol.]
[C01BA01, quinidine, The metabolism of Ethinylestradiol can be decreased when combined with Quinidine.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Ethinylestradiol.]
[A02BA02, ranitidine, The metabolism of Ethinylestradiol can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of liver damage can be increased when Reserpine is combined with Ethinylestradiol.]
[J04AB02, rifampin, The metabolism of Ethinylestradiol can be increased when combined with Rifampicin.]
[J01AA09, rolitetracycline, The serum concentration of Ethinylestradiol can be decreased when it is combined with Rolitetracycline.]
[S01BC08, salicylic acid, Ethinylestradiol may increase the excretion rate of Salicylic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA06, secobarbital, The metabolism of Ethinylestradiol can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The bioavailability of Selegiline can be increased when combined with Ethinylestradiol.]
[L01FA03, obinutuzumab, Ethinylestradiol may increase the thrombogenic activities of Obinutuzumab.]
[M05BX04, denosumab, Ethinylestradiol may increase the thrombogenic activities of Denosumab.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Ethinylestradiol.]
[C03DA01, spironolactone, Ethinylestradiol may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[A05AA01, chenodeoxycholic acid, The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Ethinylestradiol.]
[D11AX24, deoxycholic acid, The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Ethinylestradiol.]
[D07AB02, hydrocortisone butyrate, The serum concentration of Hydrocortisone butyrate can be increased when it is combined with Ethinylestradiol.]
[H02CA04, levoketoconazole, The metabolism of Ethinylestradiol can be decreased when combined with Levoketoconazole.]
[A05AA02, ursodiol, Ethinylestradiol may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
